Original Article
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
N Engl J Med 1997; 336:1216-1222April 24, 1997
- Abstract
Background
There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease.
Methods
We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3).
Results
Despite random assignment, the base-line score on the Mini–Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini–Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P = 0.012), alpha-tocopherol (670 days, P = 0.001), or combination therapy (585 days, P = 0.049), as compared with the placebo group (440 days).
Conclusions
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Media in This Article
Figure 1
Event-free Survival of 341 Patients with Alzheimer's Disease Assigned to Treatment with Selegiline, Alpha-Tocopherol, Both, or Placebo.Table 1
Base-Line Demographic and Clinical Characteristics of 341 Patients with Alzheimer's Disease Randomly Assigned to Receive Placebo, Selegiline, Alpha-Tocopherol, or Both Agents.Article Activity
- Article
Alzheimer's disease is a neurodegenerative disorder characterized by loss of memory and other cognitive abilities. Neuropathologically, the disease is characterized by the presence of neurofibrillary tangles and senile plaques, impaired synaptic function, and cell loss.1 There is a prominent loss of cholinergic, noradrenergic, and dopaminergic neurons in Alzheimer's disease.2 The pathology of the disorder may involve oxidative stress and the accumulation of free radicals, leading to excessive lipid peroxidation and neuronal degeneration in the brain.3-6
Selegiline, a monoamine oxidase inhibitor, and alpha-tocopherol may have beneficial effects in patients with Alzheimer's disease. Selegiline may act as an antioxidant, since it inhibits oxidative deamination, thereby reducing neuronal damage. The drug has been associated with an increased active life span in animals.7 Studies in patients with Parkinson's disease have demonstrated that selegiline delays the need for dopamine-replacement therapy and significantly prolongs the time during which patients function well enough to work.8
Selegiline also increases levels of catecholamines, and adrenergic stimulation may improve the cognitive deficits associated with Alzheimer's disease. In short-term trials of selegiline in patients with Alzheimer's disease, small but significant improvements in cognition9 and overall ratings of functioning10 have been reported. A longer study with a small sample yielded a similar but nonsignificant trend.11
Alpha-tocopherol (vitamin E) is a lipid-soluble vitamin that interacts with cell membranes, traps free radicals, and interrupts the chain reaction that damages cells.12 In animal models, alpha-tocopherol reduced the degeneration of hippocampal cells after cerebral ischemia13 and enhanced the recovery of motor function after spinal cord injury.14 In hypoxic cultured neurons, alpha-tocopherol inhibited lipid peroxidation15 and reduced cell death associated with β-amyloid protein.16 Although no benefit was noted in a study of alpha-tocopherol in patients with Parkinson's disease,8 there is much interest in a possible role of antioxidants in delaying the onset of Alzheimer's disease.
The primary purpose of the present study was to determine whether selegiline, alpha-tocopherol, or a combination of the two agents would slow the clinical deterioration associated with Alzheimer's disease. Although previous trials involving patients with Alzheimer's disease have focused on cognitive deterioration, our study examined functional loss. We sought to determine whether treatment with these agents could delay the time to the occurrence of clinical outcomes that reflect substantial functional deterioration.
Methods
Patients were recruited from 23 centers participating in the Alzheimer's Disease Cooperative Study (see the Appendix). A total of 341 patients with probable Alzheimer's disease of moderate severity, as measured by a Clinical Dementia Rating of 2,17 were enrolled. Informed consent was obtained from each patient or a family member. At the time of enrollment, the patients were free of other central nervous system diseases, were not taking psychoactive medications, and were residing either at home or in a supervised setting with a care giver but not in a skilled-nursing facility. The study population has been described in detail previously.18
The patients were randomly assigned (after stratification according to center with the use of a permuted-block procedure) to receive selegiline, alpha-tocopherol, selegiline and alpha-tocopherol, or placebo. Selegiline (Eldepryl, Somerset Pharmaceuticals, Tampa, Fla.) was given in a dose of 5 mg twice a day, and a racemic mixture of dl-alpha-tocopherol (vitamin E, Hoffmann–LaRoche, Nutley, N.J.) was given in a dose of 1000 IU twice a day; both agents were given in the morning and in the afternoon.
Primary Outcome Measure
The primary outcome measure was the time to the occurrence of any one of the following end points: death; institutionalization; loss of the ability to perform at least two of three basic activities of daily living (i.e., eating, grooming, using the toilet), as measured by part 2 of the Blessed Dementia Scale19; and severe dementia, defined as a Clinical Dementia Rating of 3.17 The date of death or institutionalization was used to calculate the time to either of these end points; if that date was not available, the date of the next follow-up visit was used. To calculate the time to the loss of the ability to perform activities of daily living or the occurrence of severe dementia, we used the date of the follow-up visit during which the end point was documented.18
Secondary outcome measures included measures of cognition, function, behavior, and the presence or absence of extrapyramidal signs. Cognition was assessed with the cognitive portion of the Alzheimer's Disease Assessment Scale20 and the Mini–Mental State Examination.21 Function was assessed with the total score on the Blessed Dementia Scale. This scale has two sections: instrumental activities of daily living (e.g., remembering lists and handling small sums of money) and basic activities of daily living (e.g., eating, using the toilet, and grooming). Function was also assessed with the Dependence Scale, a seven-point scale that rates the need for supervision and care.22 The Equivalent Institutional Service, a subsection of the Dependence Scale, rates the level of care received as follows: 1, limited home care; 2, care equivalent to that received in an adult care facility; and 3, care equivalent to that received in a skilled-nursing facility. Behavioral disturbance was assessed with the Behavior Rating Scale for Dementia.23 Extrapyramidal signs were assessed with a modification of the motor part of the Unified Parkinson's Disease Rating Scale.24 A score of 2 or higher on any item was considered to indicate the presence of extrapyramidal signs.
Safety
To assess the safety of treatment, routine blood and urine analyses were performed and vital signs and weight were checked at all clinic visits. Medical events that occurred during the treatment period were reported as adverse events. These events were categorized on the basis of the description provided.
Follow-up
Assessments were conducted one month after enrollment and at three-month intervals for the remainder of the two-year study period. At each interval, every effort was made to assess primary and secondary outcomes, regardless of whether an end point had been reached or the medication had been discontinued.
Drug-Level Monitoring
The level of alpha-tocopherol was monitored by measuring serum tocopherol concentrations, and the level of selegiline was monitored by measuring amphetamine, its major metabolite, in urine. Tests for selegiline were considered positive if the presence of amphetamine was detected in 75 percent of the urine samples obtained from a given patient. Tests for alpha-tocopherol were considered positive if serum tocopherol levels were 2.0 mg per deciliter (46 μmol per liter) or higher in 75 percent of the blood samples obtained from a given patient.
Statistical Analysis
Base-line differences in predetermined potential covariates among the four groups were examined with the use of either analysis of variance or chi-square analyses, as appropriate. The variables examined included demographic characteristics (age, duration of illness, education, and sex) and clinical characteristics (scores on the Mini–Mental State Examination and Blessed Dementia Scale and the presence or absence of extrapyramidal signs). The variables that differed significantly among the groups at the 0.1 level were examined as predictors of the primary outcome, and the significant predictors were included in the analysis of the treatment effect.
The primary intention-to-treat analysis of treatment efficacy compared each treatment with placebo with the use of a Kaplan–Meier estimation25 and log-rank testing for the unadjusted analysis and the Cox proportional-hazards model to control for any imbalance in the predetermined covariates among the four groups. The relative risk associated with treatment as compared with placebo was measured with the use of the risk ratio derived from the Cox model, with significance levels adjusted for multiple comparisons.26 The median time to an end point was estimated on the basis of survival curves generated from the Cox model.
The secondary outcomes were examined with the use of survival analyses, analysis of variance, or analysis of covariance, as appropriate. Missing values were imputed by using the last observation carried forward. For each of these analyses, the rate of study completion was compared among the four groups. If significant differences were observed (P<0.1), the time enrolled in the study was included as a covariate in the model.
Safety data were examined by using Fisher's exact test to compare the frequency of abnormal findings (e.g., adverse events or abnormalities in laboratory results or vital signs) among the study groups.
A safety-monitoring committee reviewed the safety data coded according to the study group or uncoded, as needed. The committee was responsible for recommending changes in the protocol or early termination of the study, if necessary. A preplanned interim analysis was conducted at the midpoint of the study, with prespecified rules for termination.27 Log-rank tests were used for the unadjusted analysis, and the Cox model was used to adjust for age, score on the Mini–Mental State Examination, and sex. No significant treatment effects were observed in the interim analysis.
Results
Table 1Table 1
Base-Line Demographic and Clinical Characteristics of 341 Patients with Alzheimer's Disease Randomly Assigned to Receive Placebo, Selegiline, Alpha-Tocopherol, or Both Agents. shows the demographic and clinical characteristics of each study group at base line. There was a trend toward a significant difference among the groups in the score on the Mini–Mental State Examination (P = 0.071), with the placebo group having the highest score and the alpha-tocopherol group having the lowest score. There were no significant differences in the other variables. In the Cox model, a higher score on the Mini–Mental State Examination was strongly associated with a delay in the primary outcome (risk ratio, 0.909 per unit increase in score; P<0.001) and was also associated with a delay in each of the individual outcomes.Primary Outcome Measure
The results of unadjusted comparisons of selegiline with placebo (risk ratio, 0.72; P = 0.087), alpha-tocopherol with placebo (risk ratio, 0.70; P = 0.077), and combined treatment with placebo (risk ratio, 0.78; P = 0.21) were not statistically significant (Figure 1AFigure 1
Event-free Survival of 341 Patients with Alzheimer's Disease Assigned to Treatment with Selegiline, Alpha-Tocopherol, Both, or Placebo., Figure 1B, and Figure 1C). However, when the base-line score on the Mini–Mental State Examination was included as a covariate (Figure 1D), a significant delay in the primary outcome was found with selegiline (risk ratio, 0.57; P = 0.012), alpha-tocopherol (risk ratio, 0.47; P = 0.001), and combination therapy (risk ratio, 0.69; P = 0.049). The estimated increase in median survival was 230 days for the patients receiving alpha-tocopherol, 215 days for those receiving selegiline, and 145 days for those receiving both, as compared with the patients receiving placebo (Table 2Table 2
Primary Outcome and Median Survival According to Study Group.).We also examined the effect of treatment on each of the individual end points in the primary outcome measure (Table 3Table 3
Percentage of Patients Reaching Each End Point, According to Study Group.). For the end point of institutionalization, the comparison of alpha-tocopherol with placebo showed a significant treatment effect (risk ratio, 0.42; P = 0.003). No statistically significant differences among the groups were observed for the other end points.Secondary Outcome Measures
The results of the analyses of secondary outcome measures are presented in Table 4Table 4
Secondary Outcome Measures.. In some cases, the cognitive data were not complete because of the development of advanced dementia. The mean time to the last score on the Mini–Mental State Examination was 15.6 months, and the scores did not differ significantly among the four groups. Changes from the base-line scores also did not differ significantly among the groups (P = 0.83).The change in the performance on the cognitive portion of the Alzheimer's Disease Assessment Scale was calculated as the difference between the base-line score and the score at the last visit. The mean time to the last score was 12.4 months. The changes in the scores did not differ significantly among the four groups (P = 0.17). The use of the base-line score on the Mini–Mental State Examination and the time in the study as covariates did not change these results.
For the Blessed Dementia Scale, the mean time to the last observation was 20.0 months. The change in the score from base line to the last evaluation differed significantly among the groups (P=0.004), with the base-line score on the Mini–Mental State Examination included as a covariate. Pairwise post hoc comparisons showed significant differences between each treatment group and the placebo group, with a benefit associated with treatment.
At base line, 3 percent of the patients received the maximal rating of 3 for level of care. For the 331 patients who were not at level 3 at base line, similar proportions in the four groups received higher ratings at the last evaluation.
At base line, 3 percent of the patients had a maximal dependence level, defined as the need for assistance with moving, turning, eating, or using the toilet. For the 332 patients who were not at the maximal level at base line, the Cox model demonstrated a significant overall effect of treatment in maintaining a lower level of dependence (P = 0.039). Patients treated with alpha-tocopherol alone or combined with selegiline required significantly less supervision than those receiving placebo (P = 0.021 and 0.014, respectively).
Changes in the scores on the Behavioral Rating Scale for Dementia differed significantly among the four groups (P = 0.020). The patients receiving combined therapy had a decrease in behavioral symptoms, whereas those receiving placebo had an increase in symptoms. The results of no other comparisons were significant.
Extrapyramidal signs were present at base line in 22 percent of the patients, with no significant differences among the four groups. There were no differences in the frequency of new extrapyramidal signs among the groups (P = 0.59).
Safety Data
A total of 49 categories of adverse events were defined. There were significant differences among the groups in three categories: dental events, which were defined as any event that led to dental treatment (P = 0.023); falls (P = 0.005); and syncopal episodes (P = 0.031) (Table 5Table 5
Frequency of Adverse Events According to Study Group.). The frequency of other adverse events, including cardiac, gastrointestinal, dermatologic, and psychiatric or other neurologic symptoms, did not differ significantly among the groups. Overall, there were no statistically significant differences among the groups in adverse-event categories after adjustment for multiple comparisons.26 There were also no significant differences in vital signs, weight change, or laboratory values among the groups.The death rate was 10.3 percent, which is similar to that reported in another cohort of patients with Alzheimer's disease of the same severity.17 We also examined the cause of death and found no specific pattern associated with treatment.
Drug-Level Monitoring
Urine samples were available from 318 patients for analysis of amphetamine levels. The proportion of patients with positive tests for selegiline was 93 percent in the combined group, 98 percent in the selegiline group, 11 percent in the alpha-tocopherol group, and 13 percent in the placebo group. Serum samples were available from 332 patients. The proportion of patients with positive tests for alpha-tocopherol was 91 percent in the combined group, 93 percent in the alpha-tocopherol group, 9 percent in the selegiline group, and 12 percent in the placebo group.
Discussion
In this double-blind, controlled study of patients with Alzheimer's disease, treatment with selegiline or alpha-tocopherol or both was beneficial in delaying the primary outcome of disease progression. The median time to the primary outcome was longer with each treatment than with placebo. There was a trend toward a delay in reaching each of the individual end points making up the primary outcome, with a significant delay in institutionalization in the alpha-tocopherol group. There were also significant delays in the deterioration of the performance of activities of daily living and the need for care. These findings should be of interest since, to date, no treatment for Alzheimer's disease has shown similar benefits with respect to these outcomes. The possibility that our findings reflect aberrations in the placebo group is unlikely, since the patients in this group reached the end points at the same rate as patients in other multicenter studies.18
Falls and syncope were more frequent in the treatment groups, especially the group receiving combined treatment, than in the placebo group. Although similar results have been reported with selegiline, there are no such reports with alpha-tocopherol, and the reason for the increased numbers of falls and syncopal episodes in the group receiving combined treatment is unclear. However, these events did not lead to the discontinuation of treatment, and we conclude that each agent alone may be relatively well tolerated by patients with Alzheimer's disease.
There were no demonstrable differences between the results in the group receiving combined treatment and either of the groups receiving individual treatment. There are several possible explanations for the lack of an additive effect of treatment. Perhaps both agents exert their effects through the same mechanism, with either agent providing a maximal benefit. Alternatively, each agent may work through an independent mechanism, but the disease may have been sufficiently severe that no additive benefit could be observed. Finally, one agent may interfere with the absorption or metabolism of the other, resulting in an effect that is not additive.
Our findings suggest that the use of selegiline or alpha-tocopherol may delay clinically important functional deterioration in patients with Alzheimer's disease. One can only speculate about the mechanism underlying this effect. Selegiline may have enhanced the functioning of nigral neurons or enhanced their survival by inhibiting oxidative deamination. Alpha-tocopherol may have provided the same benefit, resulting in the inability to observe an additive effect in the group receiving combined treatment.
In our study, there was no improvement in cognitive test scores in any of the treatment groups. Our patients were more severely impaired than those described in other clinical trials,28,29 and our observation period was long, with a large proportion of patients who did not complete the two years of testing. However, even when we controlled for the length of the observation period, treatment had no effect on cognitive scores. The observed changes in the scores on the cognitive portion of the Alzheimer's Disease Assessment Scale and the Mini–Mental State Examination are similar to those reported in other studies,30 and our findings do not suggest that the patients had reached a maximal deficit. It is possible that other features of advanced disease (e.g., behavioral disturbances and functional impairments) make it difficult to assess the cognitive domain. Although cognitive measures have typically been the index of symptomatic improvement measured over a short interval, they may not be the best measures of disease progression, particularly in a cohort of patients with moderately severe Alzheimer's disease followed for a long interval. There was a benefit of treatment associated with the score on the Blessed Dementia Scale, which includes instrumental activities of daily living — those that require cognitive function. Perhaps functional and occupational measures of cognitive capacity are better indicators of disease progression than psychometric measures.
The role of selegiline and alpha-tocopherol in the treatment of neurodegenerative diseases is currently of great interest. Selegiline delays the onset of disability in patients with Parkinson's disease.8 Previous trials of alpha-tocopherol have demonstrated no benefit in patients with Huntington's disease31 or Parkinson's disease.8 The neuronal populations involved in Alzheimer's disease are more sensitive to oxidative stress than those in other neurodegenerative diseases. Perhaps these neurons mediate the clinical end points described here. The outcome of improved function despite the absence of improved cognition raises the possibility that the effect we observed is a nonspecific health benefit to which our primary outcome was sensitive. For example, in elderly populations it has been suggested that antioxidants improve cardiovascular function32 and the immune response33 and also reduce the risk of cancer.34 Although we found no differences in the frequency of these types of adverse events in our study groups, we have no biologic data to evaluate these possible effects. The small behavioral effect that we observed is unlikely to account for these results. Perhaps cognitive measures would be sensitive to changes at earlier stages of the disease. However, only randomized clinical trials can determine the usefulness of these agents in other populations.
Both selegiline and alpha-tocopherol delay functional deterioration, particularly as reflected by the need for institutionalization, and should be considered for use in patients with moderate dementia. Convenience and cost may play a part in treatment decisions, since both agents were effective. It should be noted that statistically significant results were seen in a model that included adjustment for the base-line differences among the groups in the score on the Mini–Mental State Examination. Although this type of adjustment was used in other studies of drugs to treat Alzheimer's disease,28,29 it may limit the interpretation of these results. Replication of our findings would lend support to our data showing the efficacy of these agents. In addition, little is known about the efficacy of these compounds in other patients, such as those with mild cognitive impairment, early dementia, or the very late stages of Alzheimer's disease.
Supported by a grant (U01-AG10483) from the National Institutes of Health.
We are indebted to Somerset Pharmaceuticals for providing selegiline and to Hoffmann–LaRoche for providing alpha-tocopherol.
Source Information
From the Gertrude H. Sergievsky Center, Department of Neurology, Columbia University College of Physicians and Surgeons, New York (M.S.); the Alzheimer's Disease Cooperative Study (C.E., R.G.T., M.R.K., K.S., M.G., P.W., L.J.T.) and the Departments of Family and Preventive Medicine (R.G.T., M.R.K.) and Neurosciences (M.G., L.J.T.), University of California at San Diego, La Jolla; the Department of Neurology, Harvard Medical School, Boston (J.G.); the University of California at Irvine, Irvine (C.W.C.); the University of South Florida, Tampa (E.P.); and the University of Southern California, Los Angeles (L.S.S.).
Address reprint requests to Dr. Sano at 630 W. 168th St., Box 16, New York, NY 10032.
The members of the Alzheimer's Disease Cooperative Study are listed in the Appendix.
Appendix
The following members of the Alzheimer's Disease Cooperative Study participated in this study: S. Vicari, Southern Illinois University, Springfield; D. Bennett, C. Forchetti, and A. Levin, Rush Institute on Aging, Chicago; C. Clark, University of Pennsylvania, Philadelphia; K. Davis, P. Aisen, D. Marin, and R. Mohs, Mount Sinai School of Medicine, New York; R. Doody, E. Lipscomb, and P. Schulz, Baylor College of Medicine, Houston; S. Ferris, E. Resnick, and T. McRae, New York University Medical Center, New York; N. Foster, N. Barbas, L. Bieliauskas, and L. Bluemlein, University of Michigan, Ann Arbor; J. Growdon, N. Simonian, M. Tennis, C. Burke, A. Markus, and K. Graefe, Massachusetts General Hospital, Boston; L. Harrell, University of Alabama at Birmingham, Birmingham; C. Kawas, H. Karagiozis, and A. Morrison, Johns Hopkins University, Baltimore; J. Kaye, Oregon Health Sciences University, Portland; D. Knopman, M. Prod'Homme, and L. Langley, University of Minnesota Hospital, Minneapolis; V. Kumar, University of Miami, Miami Beach, Fla.; R. Margolin and P. Brooks, Vanderbilt University, Nashville; J. Morris and E. Rubin, Washington University Medical Center, St. Louis; R. Petersen and L. Limbo, Mayo Clinic, Rochester, Minn.; E. Pfeiffer, University of South Florida Health Sciences Center, Tampa; M. Raskind and E. Peskind, Veterans Affairs Medical Center, Seattle; M. Sano, K. Marder, K. Bell, G. Dooneief, P. Schofield, M. Chun, A. Lawton, and J. Wilson, Columbia University, New York; F. Schmitt and W. Ashford, University of Kentucky, Lexington; L. Schneider, S. Pawluczyk, J. Olin, N. Taggart, and C. Ghoush, University of Southern California, Los Angeles; W. Strittmatter and S. Wyne, Duke University, Durham, N.C.; L. Thal, W. Samuel, J. Corey-Bloom, D. Galasko, D. Bower, and V. Rice, University of California at San Diego, La Jolla; P. Whitehouse, A. Lerner, K. Horner Fedor, P. Hedera, M. Patterson, M. Sanders, and C. Zadorozny, University Hospitals of Cleveland, Cleveland. Members of the data-monitoring and data-coordinating staff: J. Bochenek, L. Simon, B. White, S. Jin, J. Jeong, L. Berkman, J. Mackell, and M. Schittini. Members of the safety-monitoring committee: E. Jackson, P. Tariot, and T. Sunderland.
- References
References
1
Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994:585-613.
2
Davies P. An update on the neurochemistry of Alzheimer disease. In: Mayeux R, Rosen WG, eds. The dementias. Vol. 38 of Advances in neurology. New York: Raven Press, 1983:75-86.
3
Harman D. The free radical theory of aging. In: Pryor WA, ed. Free radicals in biology. Vol. 5. New York: Academic Press, 1982:255-75.
4
Porta EA. Role of oxidative damage in the aging process. In: Chow CK, ed. Cellular antioxidant defense mechanisms. Vol. 3. Boca Raton, Fla.: CRC Press, 1988:1-52.
5
Smith CD ,Carney JM ,Starke-Reed PE , et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991;88:10540-10543
CrossRef | Web of Science | Medline6
Smith MA ,Perry G ,Richey PL , et al. Oxidative damage in Alzheimer's. Nature 1996;382:120-121
CrossRef | Web of Science | Medline7
Knoll J . Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983;95:57-80
CrossRef | Medline8
The Parkinson Study Group
Full Text | Web of Science | Medline9
Piccinin GL ,Finali G ,Piccirilli M . Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990;13:147-163
CrossRef | Web of Science | Medline10
Mangoni A ,Grassi MP ,Frattola L , et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991;31:100-107[Erratum, Eur Neurol 1991;31:433a.]
CrossRef | Web of Science | Medline11
Burke WJ ,Roccaforte WH ,Wengel SP ,Bayer BL ,Ranno AE ,Willcockson NK . L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-1225
Web of Science | Medline12
Halliwell B ,Gutteridge JMC . Oxygen radicals in the nervous system. Trends Neurosci 1985;8:22-26
CrossRef | Web of Science13
Hara H ,Kato H ,Kogure K . Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 1990;510:335-338
CrossRef | Web of Science | Medline14
Anderson DK ,Waters TR ,Means ED . Pretreatment with alpha tocopherol enhances neurologic recovery after experimental spinal cord compression injury. J Neurotrauma 1988;5:61-67
CrossRef | Medline15
Yoshida S ,Busto R ,Watson BD ,Santiso M ,Ginsberg MD . Postischemic cerebral lipid peroxidation in vitro: modification by dietary vitamin E. J Neurochem 1985;44:1593-1601
CrossRef | Web of Science | Medline16
Behl C ,Davis J ,Cole GM ,Schubert D . Vitamin E protects nerve cells from amyloid-beta protein toxicity. Biochem Biophys Res Commun 1992;186:944-950
CrossRef | Web of Science | Medline17
Morris JC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414
Web of Science | Medline18
Sano M ,Ernesto C ,Klauber MR , et al. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer's disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 1996;10:132-140
CrossRef | Web of Science | Medline19
Blessed G ,Tomlinson BE ,Roth M . The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811
CrossRef | Web of Science | Medline20
Rosen WG ,Mohs RC ,Davis KL . A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364
Web of Science | Medline21
Folstein MF ,Folstein SE ,McHugh PR . “Mini-Mental State“: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
CrossRef | Web of Science | Medline22
Stern Y ,Albert SM ,Sano M , et al. Assessing patient dependencein Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1994;49:M216-M22223
Tariot PN ,Mack JL ,Patterson MB , et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease: the Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995;152:1349-1357
Web of Science | Medline24
Richards M ,Marder K ,Bell K ,Dooneief G ,Mayeux R ,Stern Y . Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-1149
Web of Science | Medline25
Miller RG Jr . What price Kaplan-Meier? Biometrics 1983;39:1077-1081
CrossRef | Web of Science | Medline26
Holm S . A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
Web of Science27
Fleming TR ,Harrington DP ,O'Brien PC . Designs for group sequential tests. Control Clin Trials 1984;5:348-361
CrossRef | Medline28
Farlow M ,Gracon SI ,Hershey LA ,Lewis KW ,Sadowsky CH ,Dolan-Ureno J . A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529
CrossRef | Web of Science | Medline29
Knapp MJ ,Knopman DS ,Solomon PR ,Pendlebury WW ,Davis CS ,Gracon SI . A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
CrossRef | Web of Science | Medline30
Thal LJ ,Carta A ,Clarke WR , et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711
Web of Science | Medline31
Peyser CE ,Folstein M ,Chase GA , et al. Trial of d-α-tocopherol in Huntington's disease. Am J Psychiatry 1995;152:1771-1775
Web of Science | Medline32
Machlin LJ . Critical assessment of the epidemiological data concerning the impact of antioxidant nutrients on cancer and cardiovascular disease. Crit Rev Food Sci Nutr 1995;35:41-50
CrossRef | Web of Science | Medline33
Meydani SN ,Wu D ,Santos MS ,Hayek MG . Antioxidants and immune response in aged persons: overview of present evidence. Am J Clin Nutr 1995;62:Suppl:1462s-1476s
Web of Science | Medline34
Flagg EW ,Coates RJ ,Greenberg RS . Epidemiologic studies of antioxidants and cancer in humans. J Am Coll Nutr 1995;14:419-427
Web of Science | Medline
- Citing Articles (682)
Citing Articles
1
MK Gestuvo, WW Hung. (2012) Common dietary supplements for cognitive health. Aging Health 8:1, 89-97
CrossRef2
Karem H. Alzoubi, Omar F. Khabour, Baraa Abu Rashid, Imad M. Damaj, Heba A. Salah. (2012) The neuroprotective effect of vitamin E on chronic sleep deprivation-induced memory impairment: The role of oxidative stress. Behavioural Brain Research 226:1, 205-210
CrossRef3
Jing-Zhi Guan, Wei-Ping Guan, Toyoki Maeda, Naoki Makino. (2012) Effect of Vitamin E Administration on the Elevated Oxygen Stress and the Telomeric and Subtelomeric Status in Alzheimer’s Disease. Gerontology 58:1, 62-69
CrossRef4
Betul Catalgol, Nesrin Kartal Ozer. (2012) Protective effects of vitamin E against hypercholesterolemia-induced age-related diseases. Genes & Nutrition 7:1, 91-98
CrossRef5
Miroslav Pohanka. (2011) Alzheimer's disease and related neurodegenerative disorders: implication and counteracting of melatonin. Journal of Applied Biomedicine 9:4, 185-196
CrossRef6
Filomena Conforti, Mariangela Marrelli, Colica Carmela, Federica Menichini, Perri Valentina, Dimitar Uzunov, Giancarlo A. Statti, Pierre Duez, Francesco Menichini. (2011) Bioactive phytonutrients (omega fatty acids, tocopherols, polyphenols), in vitro inhibition of nitric oxide production and free radical scavenging activity of non-cultivated Mediterranean vegetables. Food Chemistry 129:4, 1413-1419
CrossRef7
Tommaso Iannitti, Beniamino Palmieri. 2011. Antioxidant Therapy and its Effectiveness in Oxidative Stress-Mediated Disorders. , 209-234.
CrossRef8
Renã A. S. Robinson, Gururaj Joshi, Quanzhen Huang, Rukhsana Sultana, Austin S. Baker, Jian Cai, William Pierce, Daret K. St. Clair, William R. Markesbery, D. Allan Butterfield. (2011) Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: Insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive. PROTEOMICS 11:21, 4243-4256
CrossRef9
Robert Skully, Aroob Shanaah Saleh. (2011) Aging and the Effects of Vitamins and Supplements. Clinics in Geriatric Medicine 27:4, 591-607
CrossRef10
Alan M. Mandell, Robert C. Green. 2011. Alzheimer's Disease. , 1-91.
CrossRef11
M. Obulesu, Muralidhara Rao Dowlathabad, P.V. Bramhachari. (2011) Carotenoids and Alzheimer’s Disease: An insight into therapeutic role of retinoids in animal models. Neurochemistry International 59:5, 535-541
CrossRef12
Patrizia Mecocci, Maria Cristina Polidori. (2011) Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
CrossRef13
Amy L.S. Dowling, Elizabeth Head. (2011) Antioxidants in the canine model of human aging. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
CrossRef14
Chava B. Pocernich, D. Allan Butterfield. (2011) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
CrossRef15
Magali Dumont, M. Flint Beal. (2011) Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine 51:5, 1014-1026
CrossRef16
Benjamin Le Droumaguet, Hayfa Souguir, Davide Brambilla, Romain Verpillot, Julien Nicolas, Myriam Taverna, Patrick Couvreur, Karine Andrieux. (2011) Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-β peptide and surface reorganization. International Journal of Pharmaceutics 416:2, 453-460
CrossRef17
Martijn C. de Wilde, Patrick J.G.H. Kamphuis, John W.C. Sijben, Phillip Scheltens. (2011) Utility of imaging for nutritional intervention studies in Alzheimer's disease. European Journal of Pharmacology 668, S59-S69
CrossRef18
Ira T. Lott, Eric Doran, Vinh Q. Nguyen, Anne Tournay, Elizabeth Head, Daniel L. Gillen. (2011) Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation. American Journal of Medical Genetics Part A 155:8, 1939-1948
CrossRef19
Maire E. Percy, Theo P.A. Kruck, Aileen I. Pogue, Walter J. Lukiw. (2011) Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. Journal of Inorganic Biochemistry
CrossRef20
Jone López-Erauskin, Stéphane Fourcade, Jorge Galino, Montserrat Ruiz, Agatha Schlüter, Alba Naudi, Mariona Jove, Manuel Portero-Otin, Reinald Pamplona, Isidre Ferrer, Aurora Pujol. (2011) Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Annals of Neurology 70:1, 84-92
CrossRef21
Carolyn O’Driscoll, Francesca Doonan, Nuria Sanvicens, Angel Messeguer, Thomas G. Cotter. (2011) A novel free radical scavenger rescues retinal cells in vivo. Experimental Eye Research 93:1, 65-74
CrossRef22
Vijayasree V. Giridharan, Rajarajan A. Thandavarayan, Tetsuya Konishi. (2011) Effect of Shengmai-san on Cognitive Performance and Cerebral Oxidative Damage in BALB/c Mice. Journal of Medicinal Food 14:6, 601-609
CrossRef23
Koji Fukui, Hirokatsu Takatsu, Tatsuro Koike, Shiro Urano. (2011) Hydrogen peroxide induces neurite degeneration: Prevention by tocotrienols. Free Radical Research 45:6, 681-691
CrossRef24
Deepak Sachdeva, Alistair Burns. (2011) Dimebolin in Dementia. CNS Neuroscience & Therapeutics 17:3, 199-205
CrossRef25
Milap A. Nowrangi, Vani Rao, Constantine G. Lyketsos. (2011) Epidemiology, Assessment, and Treatment of Dementia. Psychiatric Clinics of North America 34:2, 275-294
CrossRef26
Vincenzo Solfrizzi, Francesco Panza, Vincenza Frisardi, Davide Seripa, Giancarlo Logroscino, Bruno P Imbimbo, Alberto Pilotto. (2011) Diet and Alzheimer’s disease risk factors or prevention: the current evidence. Expert Review of Neurotherapeutics 11:5, 677-708
CrossRef27
Robert H. Howland. (2011) Alternative Drug Therapies for Dementia. Journal of Psychosocial Nursing and Mental Health Services 49:5, 17-20
CrossRef28
Lea C. Watson, Carmen L. Lewis, Charity G. Moore, Dilip V. Jeste. (2011) Perceptions of depression among dementia caregivers: findings from the CATIE-AD trial. International Journal of Geriatric Psychiatry 26:4, 397-402
CrossRef29
Clive Ballard, Serge Gauthier, Anne Corbett, Carol Brayne, Dag Aarsland, Emma Jones. (2011) Alzheimer's disease. The Lancet 377:9770, 1019-1031
CrossRef30
Christiane Reitz, Carol Brayne, Richard Mayeux. (2011) Epidemiology of Alzheimer disease. Nature Reviews Neurology 7:3, 137-152
CrossRef31
P.A. Adlard, A.I. Bush. (2011) The plasma membrane redox system in Alzheimer's disease. Experimental Neurology 228:1, 9-14
CrossRef32
Maryam Bagheri, Mohammad-Taghi Joghataei, Simin Mohseni, Mehrdad Roghani. (2011) Genistein ameliorates learning and memory deficits in amyloid β(1–40) rat model of Alzheimer’s disease. Neurobiology of Learning and Memory 95:3, 270-276
CrossRef33
Rodolfo Savica, Ronald C. Petersen. (2011) Prevention of Dementia. Psychiatric Clinics of North America 34:1, 127-145
CrossRef34
Ping Tou Gee. (2011) Unleashing the untold and misunderstood observations on vitamin E. Genes & Nutrition 6:1, 5-16
CrossRef35
J. K. Sahni, L. Letenneur, L. H. Dao, C. Ramassamy. 2011. Antioxidants, diet, polyphenols and dementia. , 392-419.
CrossRef36
D. Benton. 2011. Vitamin status and psychiatric disorders. , 359-391.
CrossRef37
Cornelis J. Van der Schyf, Werner J. Geldenhuys. 2011. Multimodal drugs and their future for Alzheimer's and Parkinson's disease. , 107-125.
CrossRef38
Peter Riederer, Gerd Laux. (2011) MAO-inhibitors in Parkinson's Disease. Experimental Neurobiology 20:1, 1
CrossRef39
Antoine Piau, F. Nourhashémi, C. Hein, C. Caillaud, B. Vellas. (2011) Progress in the development of new drugs in Alzheimer’s disease. The journal of nutrition, health & aging 15:1, 45-57
CrossRef40
A. Y. Estevez, J. S. Erlichman. 2011. Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. , 255-288.
CrossRef41
Martin Steinberg, Constantine G. Lyketsos. 2010. Pharmacological Therapies in Alzheimer's Disease. , 304-311.
CrossRef42
Monica Garcia-Alloza, Laura A. Borrelli, Bradley T. Hyman, Brian J. Bacskai. (2010) Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiology of Aging 31:12, 2058-2068
CrossRef43
Trent McLaughlin, Howard Feldman, Howard Fillit, Mary Sano, Frederick Schmitt, Paul Aisen, Christopher Leibman, Lisa Mucha, J. Michael Ryan, Sean D. Sullivan, D. Eldon Spackman, Peter J. Neumann, Joshua Cohen, Yaakov Stern. (2010) Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimer's and Dementia 6:6, 482-493
CrossRef44
Mitsuo Namiki. 2010. Sesame for Functional Foods. , 215-262.
CrossRef45
2010. Micronutrients in Improvement of the Standard Therapy in Traumatic Brain Injury. , 249-268.
CrossRef46
2010. Micronutrients in the Prevention and Improvement of the Standard Therapy for Alzheimer’s Disease. , 167-195.
CrossRef47
2010. Micronutrients in Improvement of the Standard Therapy in Posttraumatic Stress Disorder. , 235-247.
CrossRef48
2010. Scientific Rationale of Current Trends in Clinical Studies of Micronutrients for Prevention of Chronic Diseases. , 23-34.
CrossRef49
Athan Baillet, Vanessa Chanteperdrix, Candice Trocmé, Pierre Casez, Catherine Garrel, Gérard Besson. (2010) The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease. Neurochemical Research 35:10, 1530-1537
CrossRef50
M D Carter, G A Simms, D F Weaver. (2010) The Development of New Therapeutics for Alzheimer's Disease. Clinical Pharmacology & Therapeutics 88:4, 475-486
CrossRef51
Jack Challem. (2010) Medical Journal Watch: Context and Applications. Alternative and Complementary Therapies 16:5, 306-310
CrossRef52
H. H. Dodge, Y. Katsumata, H. Todoriki, S. Yasura, D. C. Willcox, G. L. Bowman, B. Willcox, S. Leonard, A. Clemons, B. S. Oken, J. A. Kaye, M. G. Traber. (2010) Comparisons of Plasma/Serum Micronutrients Between Okinawan and Oregonian Elders: A Pilot Study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65A:10, 1060-1067
CrossRef53
Ha Yeon Jeong, Joo Youn Kim, Hong Kyu Lee, Do Thi Ha, Kyung-Sik Song, KiHwan Bae, Yeon Hee Seong. (2010) Leaf and stem of Vitis amurensis and its active components protect against amyloid β protein (25–35)-induced neurotoxicity. Archives of Pharmacal Research 33:10, 1655-1664
CrossRef54
Barbara K. Dunn, Ellen S. Richmond, Lori M. Minasian, Anne M. Ryan, Leslie G. Ford. (2010) A Nutrient Approach to Prostate Cancer Prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutrition and Cancer 62:7, 896-918
CrossRef55
Rudy J. Castellani, Raj K. Rolston, Mark A. Smith. (2010) Alzheimer Disease. Disease-a-Month 56:9, 484-546
CrossRef56
Françoise Forette, Jean-Jacques Hauw. (2010) Traitement symptomatique de la maladie d’Alzheimer et perspectives thérapeutiques. Thérapie 65:5, 429-437
CrossRef57
Cathi Dennehy, Candy Tsourounis. (2010) A review of select vitamins and minerals used by postmenopausal women. Maturitas 66:4, 370-380
CrossRef58
Tursun Alkam, Atsumi Nitta, Yoko Furukawa-Hibi, Minae Niwa, Hiroyuku Mizoguchi, Kiyofumi Yamada, Toshitaka Nabeshima. (2010) Oral supplementation with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of memory induced by amyloid beta in mice via restraining the hyperphosphorylation of extracellular signal-regulated kinase. Behavioural Brain Research 210:2, 184-190
CrossRef59
Christine A.F. von Arnim, Ute Gola, Hans K. Biesalski. (2010) More than the sum of its parts? Nutrition in Alzheimer's disease. Nutrition 26:7-8, 694-700
CrossRef60
Hyun Pil Lee, Xiongwei Zhu, Gemma Casadesus, Rudy J Castellani, Akihiko Nunomura, Mark A Smith, Hyoung-gon Lee, George Perry. (2010) Antioxidant approaches for the treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics 10:7, 1201-1208
CrossRef61
Sally A. Frautschy, Greg M. Cole. (2010) Why Pleiotropic Interventions are Needed for Alzheimer's Disease. Molecular Neurobiology 41:2-3, 392-409
CrossRef62
Xiao-Li He, Wei-Qin Zhou, Ming-Gang Bi, Guan-Hua Du. (2010) Neuroprotective effects of icariin on memory impairment and neurochemical deficits in senescence-accelerated mouse prone 8 (SAMP8) mice. Brain Research 1334, 73-83
CrossRef63
Antoine Piau, F. Nourhashémi, C. Hein, C. Caillaud, B. Vellas. (2010) Progress in the development of new drugs in Alzheimer’s disease. The journal of nutrition, health & aging
CrossRef64
Tomasz Sobow. (2010) Combination treatments in Alzheimer’s disease: risks and benefits. Expert Review of Neurotherapeutics 10:5, 693-702
CrossRef65
Andrea Contestabile, Fabio Benfenati, Laura Gasparini. (2010) Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome. Progress in Neurobiology 91:1, 1-22
CrossRef66
Owoedimo B. Usoro, Shaker A. Mousa. (2010) Vitamin E Forms in Alzheimer's Disease: A Review of Controversial and Clinical Experiences. Critical Reviews in Food Science and Nutrition 50:5, 414-419
CrossRef67
Encarnita Raya-Ampil, Jeffrey L. Cummings. 2010. Clinical Trials in Dementia. .
CrossRef68
David J. Bonda, Xinglong Wang, George Perry, Mark A. Smith, Xiongwei Zhu. (2010) Mitochondrial Dynamics in Alzheimerʼs Disease. Drugs & Aging 27:3, 181-192
CrossRef69
Judith Neugroschl, Mary Sano. (2010) Current Treatment and Recent Clinical Research in Alzheimer's Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:1, 3-16
CrossRef70
Akito Kato-Kataoka, Masashi Sakai, Rika Ebina, Chiaki Nonaka, Tsuguyoshi Asano, Takashi Miyamori. (2010) Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints. Journal of Clinical Biochemistry and Nutrition 47:3, 246-255
CrossRef71
Mi Jin Choi, Boh Kyung Kim, Kun Young Park, Takako Yokozawa, Young Ok Song, Eun Ju Cho. (2010) Anti-aging Effects of Cyanidin under a Stress-Induced Premature Senescence Cellular System. Biological & Pharmaceutical Bulletin 33:3, 421-426
CrossRef72
Quanzhen Huang, Christopher D. Aluise, Gururaj Joshi, Rukhsana Sultana, Daret K. St. Clair, William R. Markesbery, D. Allan Butterfield. (2010) Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: Toward therapeutic modulation of mild cognitive impairment. Journal of Neuroscience Researchn/a-n/a
CrossRef73
Jeong Hwan Kim, Soo-Jin Jeong, Hee-Young Kwon, Sang Yoon Park, Hyo-Jung Lee, Hyo-Jeong Lee, John Charles Lieske, Sung-Hoon Kim. (2010) Decursin Prevents Cisplatin-Induced Apoptosis via the Enhancement of Antioxidant Enzymes in Human Renal Epithelial Cells. Biological & Pharmaceutical Bulletin 33:8, 1279-1284
CrossRef74
Kaori Ito, Sima Ahadieh, Brian Corrigan, Jonathan French, Terence Fullerton, Thomas Tensfeldt. (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimer's and Dementia 6:1, 39-53
CrossRef75
V. E. Tseilikman, A. I. Sinitsky, K. A. Poyarkov, E. V. Vojdaev. (2009) Effect of Deprenyl on Free Radical Oxidation in Rat Brain during Immobilization Stress. Bulletin of Experimental Biology and Medicine 148:6, 856-858
CrossRef76
Philine Schneider, Harald Hampel, Katharina Buerger. (2009) Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum. CNS Neuroscience & Therapeutics 15:4, 358-374
CrossRef77
Rossen Donev, Martin Kolev, Bruno Millet, Johannes Thome. (2009) Neuronal death in Alzheimer’s disease and therapeutic opportunities. Journal of Cellular and Molecular Medicine 13:11-12, 4329-4348
CrossRef78
Serge Gauthier, Philip Scheltens. (2009) Can we do better in developing new drugs for Alzheimer's disease?. Alzheimer's and Dementia 5:6, 489-491
CrossRef79
Yves Christen. 2009. Does Ginkgo biloba Extract Exert an Effect on Alzheimer’s Disease Progression?. .
CrossRef80
Francesca Mangialasche, M. Cristina Polidori, Roberto Monastero, Sara Ercolani, Cecilia Camarda, Roberta Cecchetti, Patrizia Mecocci. (2009) Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Research Reviews 8:4, 285-305
CrossRef81
Daniel M. Bittner. (2009) Combination Therapy of Acetylcholinesterase Inhibitor and Vitamin E in Alzheimer Disease. Journal of Clinical Psychopharmacology 29:5, 511-513
CrossRef82
Andreas Kern, Christian Behl. (2009) The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:10, 1124-1132
CrossRef83
Débora Delwing, Daniela Delwing de Lima, Bianca Scolaro, Gabriela G. Kuss, José G. P. Cruz, Angela T. S. Wyse. (2009) Protective effect of antioxidants on cerebrum oxidative damage caused by arginine on pyruvate kinase activity. Metabolic Brain Disease 24:3, 469-479
CrossRef84
Vijay K. Kapoor, Janhvi Dureja, Renu Chadha. (2009) Synthetic drugs with anti-ageing effects. Drug Discovery Today 14:17-18, 899-904
CrossRef85
P. Scheltens. (2009) Moving forward with nutrition in Alzheimer’s disease. European Journal of Neurology 16, 19-22
CrossRef86
Lori-Ann Christie, Wycliffe O. Opii, Elizabeth Head. (2009) Strategies for improving cognition with aging: insights from a longitudinal study of antioxidant and behavioral enrichment in canines. AGE 31:3, 211-220
CrossRef87
Toshihisa TANAKA, Hiroaki KAZUI, Golam SADIK, Hitoshi TANIMUKAI, Shinji TAGAMI, Takashi MORIHARA, Masayasu OKOCHI, Takashi KUDO, Masatoshi TAKEDA. (2009) Prevention of psychiatric illness in the elderly, I: Path to prevention of dementia. Psychogeriatrics 9:3, 111-115
CrossRef88
James C. Ogbonna. (2009) Microbiological production of tocopherols: current state and prospects. Applied Microbiology and Biotechnology 84:2, 217-225
CrossRef89
Govind T. Vatassery, W. Ed Smith, Hung T. Quach. (2009) Brains of apolipoprotein E deficient mice fed vitamin E deficient diets show alteration in handling alpha tocopherol injected into the cerebral ventricles. Journal of the Neurological Sciences 283:1-2, 195-198
CrossRef90
Sonja Gaedicke, Xiangnan Zhang, Patricia Huebbe, Christine Boesch-Saadatmandi, Yijia Lou, Ingrid Wiswedel, Andreas Gardemann, Jan Frank, Gerald Rimbach. (2009) Dietary vitamin E, brain redox status and expression of Alzheimer's disease-relevant genes in rats. British Journal of Nutrition 102:03, 398
CrossRef91
Juliana I. dos Santos, Andreimar Martins Soares, Marcos R.M. Fontes. (2009) Comparative structural studies on Lys49-phospholipases A2 from Bothrops genus reveal their myotoxic site. Journal of Structural Biology 167:2, 106-116
CrossRef92
Maurice W. Dysken, Laura Nelson Kirk, Michael Kuskowski. (2009) Changes in Vitamin E Prescribing for Alzheimer Patients. American Journal of Geriatric Psychiatry 17:7, 621-624
CrossRef93
Ronald Black, Barry Greenberg, J. Michael Ryan, Holly Posner, Jeffrey Seeburger, Joan Amatniek, Malca Resnick, Richard Mohs, David S. Miller, Daniel Saumier, Maria C. Carrillo, Yaakov Stern. (2009) Scales as outcome measures for Alzheimer's disease. Alzheimer's and Dementia 5:4, 324-339
CrossRef94
Sue Mian Then, Musalmah Mazlan, Gapor Mat Top, Wan Zurinah Wan Ngah. (2009) Is Vitamin E Toxic to Neuron Cells?. Cellular and Molecular Neurobiology 29:4, 485-496
CrossRef95
Concepción Sánchez-Moreno, Antonio Jiménez-Escrig, Antonio Martín. (2009) Stroke: roles of B vitamins, homocysteine and antioxidants. Nutrition Research Reviews 22:01, 49
CrossRef96
J Hirvonen, M Kailajärvi, T Haltia, S Koskimies, K Någren, P Virsu, V Oikonen, H Sipilä, P Ruokoniemi, K Virtanen, M Scheinin, JO Rinne. (2009) Assessment of MAO-B Occupancy in the Brain With PET and [11C]-L-Deprenyl-D2: A Dose-Finding Study With a Novel MAO-B Inhibitor, EVT 301. Clinical Pharmacology & Therapeutics 85:5, 506-512
CrossRef97
Andrea M. Weinstein, Cynthia Barton, Leslie Ross, Joel H. Kramer, Kristine Yaffe. (2009) Treatment Practices of Mild Cognitive Impairment in California Alzheimer's Disease Centers. Journal of the American Geriatrics Society 57:4, 686-690
CrossRef98
Elizabeth Head. (2009) Oxidative Damage and Cognitive Dysfunction: Antioxidant Treatments to Promote Healthy Brain Aging. Neurochemical Research 34:4, 670-678
CrossRef99
Jason Lockrow, Annamalai Prakasam, Peng Huang, Heather Bimonte-Nelson, Kumar Sambamurti, Ann-Charlotte Granholm. (2009) Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Experimental Neurology 216:2, 278-289
CrossRef100
Thomas Rival, Richard M. Page, Dhianjali S. Chandraratna, Timothy J. Sendall, Edward Ryder, Beinan Liu, Huw Lewis, Thomas Rosahl, Robert Hider, L. M. Camargo, Mark S. Shearman, Damian C. Crowther, David A. Lomas. (2009) Fenton chemistry and oxidative stress mediate the toxicity of the β-amyloid peptide in a Drosophila model of Alzheimer’s disease. European Journal of Neuroscience 29:7, 1335-1347
CrossRef101
Yolanda de Diego-Otero, Yanina Romero-Zerbo, Rajaa el Bekay, Juan Decara, Lourdes Sanchez, Fernando Rodriguez-de Fonseca, Ignacio del Arco-Herrera. (2009) α-Tocopherol Protects Against Oxidative Stress in the Fragile X Knockout Mouse: an Experimental Therapeutic Approach for the Fmr1 Deficiency. Neuropsychopharmacology 34:4, 1011-1026
CrossRef102
Roger E. Kelley, Alireza Minagar. (2009) Memory Complaints and Dementia. Medical Clinics of North America 93:2, 389-406
CrossRef103
Chailyn Nelson, Majid Fotuhi, Heidi Wengreen, Payam Mohassel. 2009. Alzheimer’s Disease. .
CrossRef104
Saravanan S. Karuppagounder, John T. Pinto, Hui Xu, Huan-Lian Chen, M. Flint Beal, Gary E. Gibson. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochemistry International 54:2, 111-118
CrossRef105
Joseph E. Gaugler, Fang Yu, Kathleen Krichbaum, Jean F. Wyman. (2009) Predictors of Nursing Home Admission for Persons with Dementia. Medical Care 47:2, 191-198
CrossRef106
George Perry, Xiongwei Zhu, Paula I. Moreira, Mark A. Smith. (2009) Altered redox balance in disease: Can we change the new equilibria?. Annals of Neurology 65:2, 121-123
CrossRef107
Joshua A. Sonnen, Eric B. Larson, Shelly L. Gray, Angela Wilson, Steven G. Kohama, Paul K. Crane, John C. S. Breitner, Thomas J. Montine. (2009) Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Annals of Neurology 65:2, 226-229
CrossRef108
Jian Chen, Weicheng Zhang, Huiling Geng, Wei Li, Guohua Hou, Aiwen Lei, Xumu Zhang. (2009) Efficient Synthesis of Chiral β-Arylisopropylamines by Using Catalytic Asymmetric Hydrogenation. Angewandte Chemie International Edition 48:4, 800-802
CrossRef109
Jian Chen, Weicheng Zhang, Huiling Geng, Wei Li, Guohua Hou, Aiwen Lei, Xumu Zhang. (2009) Efficient Synthesis of Chiral β-Arylisopropylamines by Using Catalytic Asymmetric Hydrogenation. Angewandte Chemie 121:4, 814-816
CrossRef110
Bolleddula Jayaprakasam, Kaillathe Padmanabhan, Muraleedharan G. Nair. (2009) Withanamides in Withania somnifera fruit protect PC-12 cells from β-amyloid responsible for Alzheimer's disease. Phytotherapy Researchn/a-n/a
CrossRef111
James M Stankiewicz, Steven D Brass. (2009) Role of iron in neurotoxicity: a cause for concern in the elderly?. Current Opinion in Clinical Nutrition and Metabolic Care 12:1, 22-29
CrossRef112
Hirokatsu TAKATSU, Kei OWADA, Kouichi ABE, Masahiro NAKANO, Shiro URANO. (2009) Effect of Vitamin E on Learning and Memory Deficit in Aged Rats. Journal of Nutritional Science and Vitaminology 55:5, 389-393
CrossRef113
Soon Ock Cho, Ju Yeon Ban, Joo Youn Kim, Ha Yeon Jeong, Ik Soo Lee, Kyung-Sik Song, KiHwan Bae, Yeon Hee Seong. (2009) Aralia cordata Protects Against Amyloid β Protein (25–35)–Induced Neurotoxicity in Cultured Neurons and Has Antidementia Activities in Mice. Journal of Pharmacological Sciences 111:1, 22-32
CrossRef114
A. Mancinella, M. Mancinella, G. Carpinteri, A. Bellomo, C. Fossati, V. Gianturco, A. Iori, E. Ettorre, G. Troisi, V. Marigliano. (2009) IS THERE A RELATIONSHIP BETWEEN HIGH C-REACTIVE PROTEIN (CRP) LEVELS AND DEMENTIA?. Archives of Gerontology and Geriatrics 49, 185-194
CrossRef115
Edward Alan Miller, Lon S. Schneider, Arthur Zbrozek, Robert A. Rosenheck. (2008) Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer's Disease. Value in Health 11:7, 1120-1130
CrossRef116
Domenico Praticò. (2008) Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends in Pharmacological Sciences 29:12, 609-615
CrossRef117
Lynn A. Bialowas-McGoey, Agnieszka Lesicka, Patricia M. Whitaker-Azmitia. (2008) Vitamin E increases S100B-mediated microglial activation in an S100B-overexpressing mouse model of pathological aging. Glia 56:16, 1780-1790
CrossRef118
David S. Knopman. (2008) Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. Cognitive and Behavioral Neurology 21:4, 197-201
CrossRef119
Domenico Praticò. (2008) Evidence of Oxidative Stress in Alzheimer's Disease Brain and Antioxidant Therapy. Annals of the New York Academy of Sciences 1147:1, 70-78
CrossRef120
NORSHARINA ISMAIL, MAZNAH ISMAIL, LATIFFAH A. LATIFF, MUSALMAH MAZLAN, ABDALBASIT A. MARIOD. (2008) BLACK CUMIN SEED (NIGELLA SATIVA LINN.) OIL AND ITS FRACTIONS PROTECT AGAINST BETA AMYLOID PEPTIDE-INDUCED TOXICITY IN PRIMARY CEREBELLAR GRANULE NEURONS. Journal of Food Lipids 15:4, 519-533
CrossRef121
Saeed Hosseini, Reza Ghiasvand. 2008. The Role of Diet in Slowing or Accelerating Aging. , 181-188.
CrossRef122
David Thomas. 2008. Vitamins and Health in Older Persons. , 15-28.
CrossRef123
Ging-Yuek Robin Hsiung, Howard H Feldman. (2008) Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opinion on Pharmacotherapy 9:15, 2575-2582
CrossRef124
Constantine G. Lyketsos, Christine A. Szekely, Michelle M. Mielke, Paul B. Rosenberg, Peter P. Zandi. (2008) Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. International Psychogeriatrics 20:05,
CrossRef125
Andrew Pipingas, Richard B. Silberstein, Luis Vitetta, Cindy Van Rooy, Elizabeth V. Harris, Joanna M. Young, Christopher M. Frampton, Avni Sali, Joseph Nastasi. (2008) Improved cognitive performance after dietary supplementation with a Pinus radiata bark extract Formulation. Phytotherapy Research 22:9, 1168-1174
CrossRef126
Stacey J. Bell, Gregory T. Grochoski. (2008) How Safe is Vitamin E Supplementation?. Critical Reviews in Food Science and Nutrition 48:8, 760-774
CrossRef127
Burcu Balam Yavuz, Bunyamin Yavuz, Meltem Halil, Mustafa Cankurtaran, Zekeriya Ulger, Eylem Sahin Cankurtaran, Kudret Aytemir, Servet Ariogul. (2008) Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease. International Psychogeriatrics 20:04,
CrossRef128
Joshua A. Sonnen, John C. Breitner, Mark A. Lovell, William R. Markesbery, Joseph F. Quinn, Thomas J. Montine. (2008) Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine 45:3, 219-230
CrossRef129
X. Jia, G. McNeill, A. Avenell. (2008) Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials. Journal of Human Nutrition and Dietetics 21:4, 317-336
CrossRef130
Yoshimi Nakajima, Yuta Inokuchi, Masahiro Nishi, Masamitsu Shimazawa, Kazumasa Otsubo, Hideaki Hara. (2008) Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Research 1226, 226-233
CrossRef131
Mokhtar Gad El Kareem Nasr Isaac, Rebecca Quinn, Naji Tabet, Mokhtar Gad El Kareem Nasr Isaac. 2008. Vitamin E for Alzheimer's disease and mild cognitive impairment. .
CrossRef132
S. Kushida, K. Kimoto, N. Hori, M. Toyoda, N. Karasawa, T. Yamamoto, A. Kojo, M. Onozuka. (2008) Soft-diet feeding decreases dopamine release and impairs aversion learning in Alzheimer model rats. Neuroscience Letters 439:2, 208-211
CrossRef133
Daniel H.S. Silverman, Lisa Mosconi, Linda Ercoli, Wei Chen, Gary W. Small. (2008) Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction. Seminars in Nuclear Medicine 38:4, 251-261
CrossRef134
Roy Yaari, Shubha Kumar, Pierre N Tariot. (2008) Non-cholinergic drug development for Alzheimer's disease. Expert Opinion on Drug Discovery 3:7, 745-760
CrossRef135
Eun Ju Jeong, Ki Yong Lee, Seung Hyun Kim, Sang Hyun Sung, Young Choong Kim. (2008) Cognitive-enhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine-treated mice. European Journal of Pharmacology 588:1, 78-84
CrossRef136
Tsung-Tsair Yang, Su-Jane Wang. (2008) Facilitatory effect of glutamate exocytosis from rat cerebrocortical nerve terminals by α-tocopherol, a major vitamin E component. Neurochemistry International 52:6, 979-989
CrossRef137
Paul R Solomon, Cynthia A Murphy. (2008) Early diagnosis and treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics 8:5, 769-780
CrossRef138
Eline M. van der Beek, Patrick J.G.H. Kamphuis. (2008) The potential role of nutritional components in the management of Alzheimer's Disease. European Journal of Pharmacology 585:1, 197-207
CrossRef139
Goran Bjelakovic, Dimitrinka Nikolova, Lise Lotte Gluud, Rosa G Simonetti, Christian Gluud, Goran Bjelakovic. 2008. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. .
CrossRef140
Marion Secher, Sophie Gillette-Guyonnet, Bruno Vellas. (2008) Nutrition et prévention du déclin cognitif et démence. Cahiers de Nutrition et de Diététique 43:2, 77-89
CrossRef141
Reena S. Shah, Hyoung-Gon Lee, Zhu Xiongwei, George Perry, Mark A. Smith, Rudy J. Castellani. (2008) Current approaches in the treatment of Alzheimer's disease. Biomedicine & Pharmacotherapy 62:4, 199-207
CrossRef142
Alan J. Lerner, McKee J. McClendon, Susie A. Sami, Paula K. Ogrocki, Kathryn Betts Adams, Kathleen A. Smyth. (2008) Factors Affecting Usage Patterns of Memantine in Alzheimer Disease. Alzheimer Disease & Associated Disorders 22:2, 137-143
CrossRef143
Bruce A. Yankner, Tao Lu, Patrick Loerch. (2008) The Aging Brain. Annual Review of Pathology: Mechanisms of Disease 3:1, 41-66
CrossRef144
Afonso D.L. Souza, Edson Rodrigues-Filho, Antonia Q.L. Souza, José O. Pereira, Andrana K. Calgarotto, Victor Maso, Sérgio Marangoni, Saulo L. Da Silva. (2008) Koninginins, phospholipase A2 inhibitors from endophytic fungus Trichoderma koningii. Toxicon 51:2, 240-250
CrossRef145
Shelly L. Gray, Melissa L. Anderson, Paul K. Crane, John C. S. Breitner, Wayne McCormick, James D. Bowen, Linda Teri, Eric Larson. (2008) Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults. Journal of the American Geriatrics Society 56:2, 291-295
CrossRef146
John T Little, Sally Walsh, Paul S Aisen. (2008) An update on huperzine A as a treatment for Alzheimer's disease. Expert Opinion on Investigational Drugs 17:2, 209-215
CrossRef147
Anatol Kontush, Svetlana Schekatolina. (2008) An update on using vitamin E in Alzheimer's disease. Expert Opinion on Drug Discovery 3:2, 261-271
CrossRef148
Jennifer R Evans, Katherine S Henshaw, Jennifer R Evans. 2008. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. .
CrossRef149
Martin R. Farlow, Michael L. Miller, Vojislav Pejovic. (2008) Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations. Dementia and Geriatric Cognitive Disorders 25:5, 408-422
CrossRef150
Paul S. Aisen. (2008) Leon Thal and the therapeutic age of Alzheimer’s disease. Alzheimer's and Dementia 4:1, S4-S6
CrossRef151
Kei Ohwada, Hironobu Takeda, Makiko Yamazaki, Hirosi Isogai, Masahiko Nakano, Masao Shimomura, Koji Fukui, Shiro Urano. (2008) Pyrroloquinoline Quinone (PQQ) Prevents Cognitive Deficit Caused by Oxidative Stress in Rats. Journal of Clinical Biochemistry and Nutrition 42:1, 29-34
CrossRef152
Yasukazu Yoshida, Mieko Hayakawa, Osamu Cynshi, Kou-ichi Jishage, Etsuo Niki. (2008) Acceleration of Lipid Peroxidation in .ALPHA.-Tocopherol Transfer Protein-Knockout Mice Following the Consumption of Drinking Water Containing a Radical Initiator. Journal of Oleo Science 57:10, 577-583
CrossRef153
Michael Grundman. (2008) A quarter century of advancing treatment for Alzheimer’s disease with Leon J. Thal. Alzheimer's and Dementia 4:1, S51-S55
CrossRef154
Mary Sano, Hillel Grossman, Kathleen Van Dyk. (2008) Preventing Alzheimer’s Disease. CNS Drugs 22:11, 887-902
CrossRef155
Jeffrey L. Cummings. (2008) Optimizing phase II of drug development for disease-modifying compounds. Alzheimer's and Dementia 4:1, S15-S20
CrossRef156
2008. Bibliographie. , 207-244.
CrossRef157
Christine Fernandez, Christian Derouesné. 2008. Traitement de la maladie d'Alzheimer. , 815-824.
CrossRef158
Hannes Staehelin, Pasqualina Perrig-Chiello, Sara Hutchison. 2007. Alzheimer's Disease and Other Forms of Dementia. .
CrossRef159
Lilian Thompson, Wendy Ward. 2007. Need to Optimize the Health of Women. .
CrossRef160
Patricia Huebbe, Sebastian Schaffer, Laia Jofre-Monseny, Christine Boesch-Saadatmandi, Anne-Marie Minihane, Walter E. Müller, Gunter P. Eckert, Gerald Rimbach. (2007) Apolipoprotein E genotype and alpha-tocopherol modulate amyloid precursor protein metabolism and cell cycle regulation. Molecular Nutrition & Food Research 51:12, 1510-1517
CrossRef161
Yasukazu Yoshida, Yoshiro Saito, Leslie Sargent Jones, Yasushi Shigeri. (2007) Chemical Reactivities and Physical Effects in Comparison between Tocopherols and Tocotrienols: Physiological Significance and Prospects as Antioxidants. Journal of Bioscience and Bioengineering 104:6, 439-445
CrossRef162
Richard J. Goldberg. (2007) Alzheimer’s Disease. Comprehensive Therapy 33:2, 58-64
CrossRef163
Nathan Herrmann, Serge Gauthier, Paul G. Lysy. (2007) Clinical practice guidelines for severe Alzheimer’s disease. Alzheimer's and Dementia 3:4, 385-397
CrossRef164
Russell H. Swerdlow. (2007) Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiology of Aging 28:10, 1465-1480
CrossRef165
David B. Hogan, Peter Bailey, Anne Carswell, Barry Clarke, Carole Cohen, Dorothy Forbes, Malcolm Man-Son-Hing, Krista Lanctôt, Debra Morgan, Lilian Thorpe. (2007) Management of mild to moderate Alzheimer’s disease and dementia. Alzheimer's and Dementia 3:4, 355-384
CrossRef166
Paul S. Aisen. (2007) Commentary on “The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006.”—An appraisal. Alzheimer's and Dementia 3:4, 446-448
CrossRef167
Tony K McGhie, Michaela C Walton, Laura E Barnett, Rosheila Vather, Harry Martin, Joyce Au, Peter A Alspach, Christine L Booth, Marlena C Kruger. (2007) Boysenberry and blackcurrant drinks increased the plasma antioxidant capacity in an elderly population but had little effect on other markers of oxidative stress. Journal of the Science of Food and Agriculture 87:13, 2519-2527
CrossRef168
Russell H. Swerdlow. (2007) Treating Neurodegeneration by Modifying Mitochondria: Potential Solutions to a “Complex” Problem. Antioxidants & Redox Signaling 9:10, 1591-1604
CrossRef169
Jose Viña, Mari-Carmen Gomez-Cabrera, Consuelo Borras. (2007) Fostering antioxidant defences: up-regulation of antioxidant genes or antioxidant supplementation?. British Journal of Nutrition 98:S1,
CrossRef170
Fadi Massoud, Sylvie Belleville, Howard Bergman, John Kirk, Howard Chertkow, Ziad Nasreddine, Yves Joanette, Morris Freedman. (2007) Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy. Alzheimer's and Dementia 3:4, 283-291
CrossRef171
Roberta Ricciarelli, Francesca Argellati, Maria A. Pronzato, Cinzia Domenicotti. (2007) Vitamin E and neurodegenerative diseases. Molecular Aspects of Medicine 28:5-6, 591-606
CrossRef172
Paula I. Moreira, Maria S. Santos, Catarina R. Oliveira. (2007) Alzheimer's Disease: A Lesson from Mitochondrial Dysfunction. Antioxidants & Redox Signaling 9:10, 1621-1630
CrossRef173
Mitsuo Namiki. (2007) Nutraceutical Functions of Sesame: A Review. Critical Reviews in Food Science and Nutrition 47:7, 651-673
CrossRef174
Gang Liu, Ping Men, George Perry, Mark A. Smith. 2007. Nanoparticles for the Treatment of Alzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives. .
CrossRef175
M. Weih, J. Wiltfang, J. Kornhuber. (2007) Non-pharmacologic prevention of Alzheimer’s disease: nutritional and life-style risk factors. Journal of Neural Transmission 114:9, 1187-1197
CrossRef176
José A. Luchsinger, James M. Noble, Nikolaos Scarmeas. (2007) Diet and Alzheimer’s disease. Current Neurology and Neuroscience Reports 7:5, 366-372
CrossRef177
Judith Moreines, Richard Cotter, Leon Ellenbogen. 2007. Potential Benefits for the Use of Vitamin and Mineral Supplements. , 193-219.
CrossRef178
Alistair J Stewart, Anthony Fox, Bruce H Morimoto, Illana Gozes. (2007) Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion on Investigational Drugs 16:8, 1183-1196
CrossRef179
Brendan J. Kelley, Ronald C. Petersen. (2007) Alzheimer's Disease and Mild Cognitive Impairment. Neurologic Clinics 25:3, 577-609
CrossRef180
Steve R. Pieczenik, John Neustadt. (2007) Mitochondrial dysfunction and molecular pathways of disease. Experimental and Molecular Pathology 83:1, 84-92
CrossRef181
Masahiro Okouchi, Oleksandr Ekshyyan, Magdalena Maracine, Tak Yee Aw. (2007) Neuronal Apoptosis in Neurodegeneration. Antioxidants & Redox Signaling 9:8, 1059-1096
CrossRef182
Kristyn A. Bates, Ralph N. Martins, Alan R. Harvey. (2007) Oxidative stress in a rat model of chronic gliosis. Neurobiology of Aging 28:7, 995-1008
CrossRef183
James Stankiewicz, S. Scott Panter, Mohit Neema, Ashish Arora, Courtney E. Batt, Rohit Bakshi. (2007) Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics 4:3, 371-386
CrossRef184
M OSELLA, G RE, R ODORE, C GIRARDI, P BADINO, R BARBERO, L BERGAMASCO. (2007) Canine cognitive dysfunction syndrome: Prevalence, clinical signs and treatment with a neuroprotective nutraceutical
. Applied Animal Behaviour Science 105:4, 297-310
CrossRef185
Kenichi Kitani. (2007) Pharmacological interventions in aging and age-associated disorders. Geriatrics & Gerontology International 7:2, 97-103
CrossRef186
R BADRAOUI, Z SAHNOUN, N ABDELMOULA, A HAKIM, M FKI, T REBAI. (2007) May antioxidants status depletion by Tetradifon induce secondary genotoxicity in female Wistar rats via oxidative stress?. Pesticide Biochemistry and Physiology 88:2, 149-155
CrossRef187
Seema Joshi. 2007. Nutritional Factors in Dementia. , 359-371.
CrossRef188
Martin R. Farlow, Jeffrey L. Cummings. (2007) Effective Pharmacologic Management of Alzheimer’s Disease. The American Journal of Medicine 120:5, 388-397
CrossRef189
M. C. Polidori, H. R. Griffiths, E. Mariani, P. Mecocci. (2007) Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer’s disease. Amino Acids 32:4, 553-559
CrossRef190
P.M.D. Nippak, J. Mendelson, B. Muggenburg, N.W. Milgram. (2007) Enhanced spatial ability in aged dogs following dietary and behavioural enrichment. Neurobiology of Learning and Memory 87:4, 610-623
CrossRef191
Marianna Zana, Zoltán Janka, János Kálmán. (2007) Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease. Neurobiology of Aging 28:5, 648-676
CrossRef192
Kevin R Scott, Anna M Barrett. (2007) Dementia syndromes: evaluation and treatment. Expert Review of Neurotherapeutics 7:4, 407-422
CrossRef193
Vincenzo Giordano, Gianfranco Peluso, Maurizio Iannuccelli, Paola Benatti, Raffaella Nicolai, Menotti Calvani. (2007) Systemic and Brain Metabolic Dysfunction as a New Paradigm for Approaching Alzheimer’s Dementia. Neurochemical Research 32:4-5, 555-567
CrossRef194
Encarnita Raya-Ampil, Jeffrey L. Cummings. (2007) Clinical Trials in Dementia. Progress in Neurotherapeutics and Neuropsychopharmacology 2, 39
CrossRef195
Giovanni Ciabattoni, Ettore Porreca, Concetta Di Febbo, Angelo Di Iorio, Roberto Paganelli, Tonino Bucciarelli, Lea Pescara, Letizia Del Re, Cinzia Giusti, Angela Falco, Antonella Sau, Carlo Patrono, Giovanni Davì. (2007) Determinants of platelet activation in Alzheimer's disease. Neurobiology of Aging 28:3, 336-342
CrossRef196
Shinji Soeda, Takashi Ochiai, Hiroshi Shimeno, Hiroshi Saito, Kazuho Abe, Hiroyuki Tanaka, Yukihiro Shoyama. (2007) Pharmacological activities of crocin in saffron. Journal of Natural Medicines 61:2, 102-111
CrossRef197
Simonetta Camandola, Mark P Mattson. (2007) NF-κB as a therapeutic target in neurodegenerative diseases. Expert Opinion on Therapeutic Targets 11:2, 123-132
CrossRef198
Jun Maruyama, Takahiko Yamagata, Mats Ulfendahl, Göran Bredberg, Richard A. Altschuler, Josef M. Miller. (2007) Effects of antioxidants on auditory nerve function and survival in deafened guinea pigs. Neurobiology of Disease 25:2, 309-318
CrossRef199
Meredith Harrington, Francine Grodstein. (2007) Antioxidant vitamins and Alzheimer’s disease: a review of the epidemiological literature. Aging Health 3:1, 23-32
CrossRef200
Joseph F. Quinn, Joseph R. Bussiere, Rebecca S. Hammond, Thomas J. Montine, Edward Henson, Richard E. Jones, Robert W. Stackman. (2007) Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiology of Aging 28:2, 213-225
CrossRef201
Guk-Hee Suh. (2007) Drug Therapy for Alzheimer's Disease. Journal of the Korean Medical Association 50:4, 369
CrossRef202
Marie-Laure Ancelin, Yves Christen, Karen Ritchie. (2007) Is Antioxidant Therapy a Viable Alternative for Mild Cognitive Impairment? Examination of the Evidence. Dementia and Geriatric Cognitive Disorders 24:1, 1-19
CrossRef203
A. Lewis, J.H. Miller, R.A. Lea. (2007) Monoamine oxidase and tobacco dependence. NeuroToxicology 28:1, 182-195
CrossRef204
Hila Shoval, Dov Lichtenberg, Ehud Gazit. (2007) The molecular mechanisms of the anti-amyloid effects of phenols. Amyloid 14:1, 73-87
CrossRef205
G. Waldemar, B. Dubois, M. Emre, J. Georges, I. G. McKeith, M. Rossor, P. Scheltens, P. Tariska, B. Winblad. (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology 14:1, e1-e26
CrossRef206
Craig D. Rubin. (2006) The Primary Care of Alzheimer Disease. The American Journal of the Medical Sciences 332:6, 314-333
CrossRef207
David R Thomas. (2006) Vitamin supplements for the elderly: are they worth it?. Aging Health 2:6, 883-886
CrossRef208
Takako Yokozawa, Eun Ju Cho, Takuya Okamoto, Yasuo Sei. (2006) Effects of the Chinese prescription Kangen-karyu and its crude drug Tanjin on ageing process in rats. Journal of Pharmacy and Pharmacology 58:12, 1591-1599
CrossRef209
Anton P Porsteinsson, Kelly M Cosman. (2006) Memantine in the treatment of Alzheimer’s disease. Aging Health 2:6, 891-904
CrossRef210
Mohamed Alaa Thabet, James C. M. Chan. (2006) Vitamin E in renal therapeutic regimens. Pediatric Nephrology 21:12, 1790-1801
CrossRef211
Monica Garcia-Alloza, Sarah A. Dodwell, Melanie Meyer-Luehmann, Bradley T. Hyman, Brian J. Bacskai. (2006) Plaque-Derived Oxidative Stress Mediates Distorted Neurite Trajectories in the Alzheimer Mouse Model. Journal of Neuropathology and Experimental Neurology 65:11, 1082-1089
CrossRef212
Isabelle Bairati, François Meyer, Edith Jobin, Michel Gélinas, André Fortin, Abdenour Nabid, François Brochet, Bernard Têtu. (2006) Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients. International Journal of Cancer 119:9, 2221-2224
CrossRef213
Malay K Samanta, B Wilson, K Santhi, K P Sampath Kumar, B Suresh. (2006) Alzheimer Disease and Its Management. American Journal of Therapeutics 13:6, 516-526
CrossRef214
2006. Mild Cognitive Impairment. .
CrossRef215
Howard H. Feldman, Frederick A. Schmitt, Jason T. Olin. (2006) Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment. Alzheimer Disease & Associated Disorders 20:4, 263-268
CrossRef216
Steven H. Ferris, Paul S. Aisen, Jeffrey Cummings, Douglas Galasko, David P. Salmon, Lon Schneider, Mary Sano, Peter J. Whitehouse, Steven Edland, and Leon J. Thal. (2006) ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Disease & Associated Disorders 20:Supplement 3, S109-S123
CrossRef217
Kyoko Nishi, Dorotea Mück-Šeler, Shu Hasegawa, Arata Watanabe, Mirko Diksic. (2006) Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study. Brain Research Bulletin 70:4-6, 368-377
CrossRef218
Martha Clare Morris, Bruno Vellas. (2006) Diet and prevention of dementia. Aging Health 2:5, 753-761
CrossRef219
Jeffrey L. Cummings. (2006) Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials. Alzheimer's and Dementia 2:4, 263-271
CrossRef220
Peter Lockwood, Wayne Ewy, David Hermann, Nick Holford. (2006) Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease. Pharmaceutical Research 23:9, 2050-2059
CrossRef221
Charles Ramassamy. (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. European Journal of Pharmacology 545:1, 51-64
CrossRef222
T. Augy, S. Bonin-Guillaume, O. Blin. (2006) Nouvelles approches thérapeutiques dans la Maladie d’Alzheimer. L'Encéphale 32:4, 641-649
CrossRef223
Teresa Montiel, Ricardo Quiroz-Baez, Lourdes Massieu, Clorinda Arias. (2006) Role of oxidative stress on β-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: Protection by antioxidants. Experimental Neurology 200:2, 496-508
CrossRef224
A.C. Ludolph. (2006) 135th ENMC International Workshop: Nutrition in Amyotrophic Lateral Sclerosis 18–20 of March 2005, Naarden, The Netherlands. Neuromuscular Disorders 16:8, 530-538
CrossRef225
Jeffrey L. Cummings, Thomas McRae, Richard Zhang. (2006) Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders. American Journal of Geriatric Psychiatry 14:7, 605-612
CrossRef226
Kaj Blennow, Mony J de Leon, Henrik Zetterberg. (2006) Alzheimer's disease. The Lancet 368:9533, 387-403
CrossRef227
Constantine G. Lyketsos, Christopher C. Colenda, Cornelia Beck, Karen Blank, Murali P. Doraiswamy, Douglas A. Kalunian, Kristine Yaffe. (2006) Position Statement of the American Association for Geriatric Psychiatry Regarding Principles of Care for Patients With Dementia Resulting From Alzheimer Disease. American Journal of Geriatric Psychiatry 14:7, 561-573
CrossRef228
Allan Levey, James Lah, Felicia Goldstein, Kyle Steenland, Donald Bliwise. (2006) Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer's disease. Clinical Therapeutics 28:7, 991-1001
CrossRef229
Akihiko Nunomura, Rudy J. Castellani, Xiongwei Zhu, Paula I. Moreira, George Perry, Mark A. Smith. (2006) Involvement of Oxidative Stress in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology 65:7, 631-641
CrossRef230
Ennio Esposito. 2006. Role of Nutritional Antioxidants in the Prevention and Treatment of Neurodegenerative Disorders. , 129-178.
CrossRef231
Colin L. Masters, Roberto Cappai, Kevin J. Barnham, Victor L. Villemagne. (2006) Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry 97:6, 1700-1725
CrossRef232
Paula I Moreira, Xiongwei Zhu, Akihiko Nunomura, Mark A Smith, George Perry. (2006) Therapeutic options in Alzheimer’s disease. Expert Review of Neurotherapeutics 6:6, 897-910
CrossRef233
M. Grazina, J. Pratas, F. Silva, S. Oliveira, I. Santana, C. Oliveira. (2006) Genetic basis of Alzheimer's dementia: role of mtDNA mutations. Genes, Brain and Behavior 5, 92-107
CrossRef234
Anthony R White, Kevin J Barnham, Ashley I Bush. (2006) Metal homeostasis in Alzheimer’s disease. Expert Review of Neurotherapeutics 6:5, 711-722
CrossRef235
Huai yong Cheng. (2006) Can Combination Drug Therapy Potentially Reduce Multiple Medications and Polypharmacy in Nursing Homes?. Journal of the American Medical Directors Association 7:4, 269
CrossRef236
Hee Kee Kim, Jae Hyo Kim, Xiu Gao, Jun-Li Zhou, Inhyung Lee, Kyungsoon Chung, Jin Mo Chung. (2006) Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain. PAIN 122:1-2, 53-62
CrossRef237
Carolyn W Zhu, Mary Sano. (2006) Economic considerations in the management of Alzheimer's disease. Clinical Interventions in Aging 1:2, 143-154
CrossRef238
Tae-Suk Kim, Chi-Un Pae, Su-Jung Yoon, Woo-Young Jang, Nam Jin Lee, Jung-Jin Kim, Soo-Jung Lee, Chul Lee, In-Ho Paik, Chang-Uk Lee. (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 21:4, 344-348
CrossRef239
Robert C. Green, Sally E. McNagny, Parimala Jayakumar, L. Adrienne Cupples, Kelly Benke, Lindsay A. Farrer. (2006) Statin use and the risk of Alzheimer’s disease: The MIRAGE Study. Alzheimer's and Dementia 2:2, 96-103
CrossRef240
Musalmah Mazlan, Then Sue-Mian, Gapor Mat Top, Wan Zurinah Wan Ngah. (2006) Comparative effects of α-tocopherol and γ-tocotrienol against hydrogen peroxide induced apoptosis on primary-cultured astrocytes. Journal of the Neurological Sciences 243:1-2, 5-12
CrossRef241
John B. Standridge. (2006) Current Status and Future Promise of Pharmacotherapeutic Strategies for Alzheimer’s Disease. Journal of the American Medical Directors Association 7:3, S46-S51
CrossRef242
V. S. Nedzvetsky, M. Tuzcu, A. Yasar, A. A. Tikhomirov, G. Baydas. (2006) Effects of vitamin E against aluminum neurotoxicity in rats. Biochemistry (Moscow) 71:3, 239-244
CrossRef243
Min-Young Um, Won-Hee Choi, Ji-Yun Aan, Sung-Ran Kim, Tae-Youl Ha. (2006) Protective effect of Polygonum multiflorum Thunb on amyloid β-peptide 25-35 induced cognitive deficits in mice. Journal of Ethnopharmacology 104:1-2, 144-148
CrossRef244
Angelo Del Parigi, Francesco Panza, Cristiano Capurso, Vincenzo Solfrizzi. (2006) Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin 69:1, 1-19
CrossRef245
Kenjiro Ono, Kazuhiro Hasegawa, Hironobu Naiki, Masahito Yamada. (2006) Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro. Neurochemistry International 48:4, 275-285
CrossRef246
Akram Eidi, Maryam Eidi, Gelavij Mahmoodi, Shahrbanoo Oryan. (2006) Effect of vitamin E on memory retention in rats: Possible involvement of cholinergic system. European Neuropsychopharmacology 16:2, 101-106
CrossRef247
A. Lleó, S.M. Greenberg, J.H. Growdon. (2006) Current Pharmacotherapy for Alzheimer's Disease. Annual Review of Medicine 57:1, 513-533
CrossRef248
B. BERT, S. HARMS, B. LANGEN, H. FINK. (2006) Clomipramine and selegiline: do they influence impulse control?. Journal of Veterinary Pharmacology and Therapeutics 29:1, 41-47
CrossRef249
Arthur V Everitt, Sarah N Hilmer, Jennie C Brand-Miller, Hamish A Jamieson, A Stewart Truswell, Anita P Sharma, Rebecca S Mason, Brian J Morris, David G Le Couteur. (2006) Dietary approaches that delay age-related diseases. Clinical Interventions in Aging 1:1, 11-31
CrossRef250
David R Thomas. (2006) Vitamins in aging, health, and longevity. Clinical Interventions in Aging 1:1, 81-91
CrossRef251
Nao-omi OMOI, Masaya ARAI, Mitsunari SAITO, Hirokatsu TAKATSU, Akira SHIBATA, Kenji FUKUZAWA, Kazue SATO, Kouichi ABE, Koji FUKUI, Shiro URANO. (2006) Influence of Oxidative Stress on Fusion of Pre-Synaptic Plasma Membranes of the Rat Brain with Phosphatidyl Choline Liposomes, and Protective Effect of Vitamin E. Journal of Nutritional Science and Vitaminology 52:4, 248-255
CrossRef252
Dean M Robinson, Gillian M Keating. (2006) Memantine. Drugs 66:11, 1515-1534
CrossRef253
Mayur S. Tripathi, Bhagavan S. Jandhyala. (2006) Evaluation of the Protective Effects of Histamine and 5-hydroxytryptamine Receptor Antagonists Against the Lethal Toxicity Induced by Oxygen Free Radicals in Rats. Clinical and Experimental Hypertension 28:2, 109-119
CrossRef254
Okezie I. Aruoma, Buxiang Sun, Hajime Fujii, Vidushi S. Neergheen, Theeshan Bahorun, Kyung-Sun Kang, Mi-Kyung Sung. (2006) Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. BioFactors 27:1-4, 245-265
CrossRef255
Lon S. Schneider. (2006) The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?. International Journal of Geriatric Psychiatry 21:1, 9-13
CrossRef256
Michael H??ll, Mathias Berger, Michael Heneka. (2006) Disease-Modifying Therapies in Alzheimer???s Disease. Drugs 66:16, 2075-2093
CrossRef257
Jeffrey L. Cummings, Kate Zhong. (2006) Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nature Reviews Drug Discovery 5:1, 64-74
CrossRef258
David Benton, K. Wolfgang Kallus, Jeroen A. J. Schmitt. (2005) How should we measure nutrition-induced improvements in memory?. European Journal of Nutrition 44:8, 485-498
CrossRef259
Keisuke Hirai, Atsushi Takeda, Akihiko Nunomura, MarkA Smith, Hyoung-gon Lee, Xiongwei Zhu, James Joseph, George Perry, Kelly Drew. 2005. Oxidative Adaptation in Aging and Alzheimer’s Disease. , 117-125.
CrossRef260
Ho Jin Heo, Dae-Ok Kim, Chang Yong Lee. 2005. Apple Phenolics and Alzheimer's Disease. , 247-263.
CrossRef261
Harry Ischiropoulos, Joseph Mazzulli, Summer Lind. 2005. Reactive Oxygen and Nitrogen Species. , 107-119.
CrossRef262
Jackob Moskovitz, Ashley Bush. 2005. Methionine Sulfoxide Reductase System. , 199-212.
CrossRef263
Matthew Picklo Sr. 2005. The Disposition of Lipid-Derived Carbonyls in Alzheimer’s Disease. , 181-197.
CrossRef264
Monica Garcia-Alloza, Brian Bacskai, Sarah Dodwell. 2005. Direct Evaluation of Alzheimer’s Disease-Specific Oxidative Stress with Multiphoton Microscopy. , 27-42.
CrossRef265
Akihiko Nunomura, Xiongwei Zhu, Paula Moreira, George Perry, Mark Smith. 2005. Antioxidant Therapies in the Prevention and Treatment of Alzheimer Disease. , 131-145.
CrossRef266
Carl Cotman, Elizabeth Head. 2005. Nutritional Antioxidant Enrichment and Improved Cognitive Function in Canines. , 213-223.
CrossRef267
Francieli M. Stefanello, Fábria Chiarani, Andréa G. Kurek, Clovis M.D. Wannmacher, Moacir Wajner, Angela T.S. Wyse. (2005) Methionine alters Na+,K+-ATPase activity, lipid peroxidation and nonenzymatic antioxidant defenses in rat hippocampus. International Journal of Developmental Neuroscience 23:7, 651-656
CrossRef268
Hannes B. Staehelin. (2005) Micronutrients and Alzheimer's disease. Proceedings of the Nutrition Society 64:04, 565-570
CrossRef269
Mustafa M. Husain, Robert K. Garrett. (2005) Clinical Diagnosis and Management of Alzheimer's Disease. Neuroimaging Clinics of North America 15:4, 767-777
CrossRef270
Bruno P. Imbimbo, Jay Lombard, Nunzio Pomara. (2005) Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America 15:4, 727-753
CrossRef271
Howard S. Kirshner. (2005) Mild cognitive impairment: To treat or not to treat. Current Neurology and Neuroscience Reports 5:6, 455-457
CrossRef272
Karen B. Hirschman, Colette M. Joyce, Bryan D. James, Sharon X. Xie, David J. Casarett, Jason H.T. Karlawish. (2005) Would Caregivers of Alzheimer Disease Patients Involve Their Relative in a Decision to Use an AD-Slowing Medication?. American Journal of Geriatric Psychiatry 13:11, 1014-1021
CrossRef273
Marie Céleste de Jesus Ferreira, Nadine Crouzin, Gérard Barbanel, Catherine Cohen-Solal, Max Récasens, Michel Vignes, Janique Guiramand. (2005) A transient treatment of hippocampal neurons with α-tocopherol induces a long-lasting protection against oxidative damage via a genomic action. Free Radical Biology and Medicine 39:8, 1009-1020
CrossRef274
Sevil Yasar, Jozsef Gaal, Zuzana Justinova, Jack Bergman. (2005) Discriminative stimulus and reinforcing effects of p-fluoro-l-deprenyl in monkeys. Psychopharmacology 182:1, 95-103
CrossRef275
Yvette Akwa, Herv?? Allain, Dani??le Bentue-Ferrer, Claudine Berr, R??gis Bordet, Hugo Geerts, Andr?? Nieoullon, Brigitte Onteniente, Martine Vercelletto. (2005) Neuroprotection and Neurodegenerative Diseases. Alzheimer Disease & Associated Disorders 19:4, 226-239
CrossRef276
Peter J. Whitehouse, Eric T. Juengst. (2005) Antiaging Medicine and Mild Cognitive Impairment: Practice and Policy Issues for Geriatrics. Journal of the American Geriatrics Society 53:8, 1417-1422
CrossRef277
Serge Gauthier. (2005) Pharmacotherapy of amnestic mild cognitive impairment: lessons from the Memory Impairment Study. Aging Health 1:1, 37-38
CrossRef278
R. Pulido, A. Jimenez-Escrig, L. Orensanz, F. Saura-Calixto, A. Jimenez-Escrig. (2005) Study of plasma antioxidant status in Alzheimer's disease. European Journal of Neurology 12:7, 531-535
CrossRef279
Antonio Cherubini, Antonio Martin, Cristina Andres-Lacueva, Angelo Di Iorio, Marco Lamponi, Patrizia Mecocci, Benedetta Bartali, Annamaria Corsi, Umberto Senin, Luigi Ferrucci. (2005) Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiology of Aging 26:7, 987-994
CrossRef280
D. G. McDaid, E.-M. Kim, R. E. Reid, J. C. Leslie, J. Cleary, E. O??Hare. (2005) Parenteral antioxidant treatment preserves temporal discrimination following intrahippocampal aggregated A??(1???42) injections. Behavioural Pharmacology 16:4, 237-242
CrossRef281
Scott M. Dinehart, Lance Henry. (2005) Dietary Supplements: Altered Coagulation and Effects on Bruising. Dermatologic Surgery 31, 819-826
CrossRef282
Blacker, Deborah, . (2005) Mild Cognitive Impairment — No Benefit from Vitamin E, Little from Donepezil. New England Journal of Medicine 352:23, 2439-2441
Full Text283
Petersen, Ronald C., Thomas, Ronald G., Grundman, Michael, Bennett, David, Doody, Rachelle, Ferris, Steven, Galasko, Douglas, Jin, Shelia, Kaye, Jeffrey, Levey, Allan, Pfeiffer, Eric, Sano, Mary, van Dyck, Christopher H., Thal, Leon J., . (2005) Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine 352:23, 2379-2388
Full Text284
Lora Talley Watts, Mary Latha Rathinam, Steven Schenker, George I. Henderson. (2005) Astrocytes protect neurons from ethanol-induced oxidative stress and apoptotic death. Journal of Neuroscience Research 80:5, 655-666
CrossRef285
Joann T. Tschanz, Katherine Treiber, Maria C. Norton, Kathleen A. Welsh-Bohmer, Leslie Toone, Peter P. Zandi, Christine A. Szekely, Constantine Lyketsos, John C. S. Breitner, . (2005) A Population Study of Alzheimer's Disease: Findings From the Cache County Study on Memory, Health, and Aging. Care Management Journals 6:2, 107-114
CrossRef286
K. B. Hirschman, C. M. Joyce, B. D. James, S. X. Xie, J. H. T. Karlawish. (2005) Do Alzheimer's Disease Patients Want to Participate in a Treatment Decision, and Would Their Caregivers Let Them?. The Gerontologist 45:3, 381-388
CrossRef287
Paul S. Aisen, Arthur J. Dalton, Mary Sano, Ira T. Lott, H. F. Andrews, W.-Y. Tsai, . (2005) Design and Implementation of a Multicenter Trial of Vitamin E in Aging Individuals with Down Syndrome. Journal of Policy and Practice in Intellectual Disabilities 2:2, 86-93
CrossRef288
Darryl Potyk. (2005) Treatments for Alzheimer Disease. Southern Medical Journal 98:6, 628-635
CrossRef289
Thomas J. Montine, Jason D. Morrow. (2005) Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. The American Journal of Pathology 166:5, 1283-1289
CrossRef290
Daniela Delwing, Fábria Chiarani, Caren S. Bavaresco, Clóvis M.D. Wannmacher, Moacir Wajner, Carlos S. Dutra-Filho, Angela T.S. Wyse. (2005) Protective effect of antioxidants on brain oxidative damage caused by proline administration. Neuroscience Research 52:1, 69-74
CrossRef291
John B. Standridge. (2005) Current Status and Future Promise of Pharmacotherapeutic Strategies for Alzheimer’s Disease. Journal of the American Medical Directors Association 6:3, 194-199
CrossRef292
Mark A. Smith, Akihiko Nunomura, Hyoung-gon Lee, Xiongwei Zhu, Paula I. Moreira, Jesús Avila, George Perry. (2005) Chronological primacy of oxidative stress in Alzheimer disease. Neurobiology of Aging 26:5, 579-580
CrossRef293
David Schubert. (2005) Glucose metabolism and Alzheimer's disease. Ageing Research Reviews 4:2, 240-257
CrossRef294
Randall L. Woltjer, William Nghiem, Izumi Maezawa, Dejan Milatovic, Tomas Vaisar, Kathleen S. Montine, Thomas J. Montine. (2005) Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. Journal of Neurochemistry 93:4, 1047-1056
CrossRef295
Nancy J. Roizen. (2005) Complementary and alternative therapies for Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews 11:2, 149-155
CrossRef296
G. Moulin-Romsee, A. Maes, D. Silverman, L. Mortelmans, K. Van Laere. (2005) Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. European Journal of Neurology 12:4, 254-263
CrossRef297
John C Morris. (2005) Dementia Update 2005. Alzheimer Disease & Associated Disorders 19:2, 100-117
CrossRef298
Christina T. Siwak, P. Dwight Tapp, Elizabeth Head, Steven C. Zicker, Heather L. Murphey, Bruce A. Muggenburg, Candace J. Ikeda-Douglas, Carl W. Cotman, Norton W. Milgram. (2005) Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:3, 461-469
CrossRef299
Gary Landsberg. (2005) Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:3, 471-479
CrossRef300
Paul S. Aisen. (2005) Emerging treatment strategies for alzheimer’s disease. Current Psychosis & Therapeutics Reports 3:1, 15-19
CrossRef301
Sheikh Arshad Saeed ., Mian Zainul Sajadeen Urfy ., Talaha Mubarak Ali ., , Farhad Wazirali Khimani ., Anwar-ul-Hassan Gilani .. (2005) Antioxidants: Their Role in Health and Disease. International Journal of Pharmacology 1:3, 226-233
CrossRef302
Steven C. Zicker. (2005) Cognitive and behavioral assessment in dogs and pet food market applications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:3, 455-459
CrossRef303
Maria Dawn-Linsley, Fatma J. Ekinci, Daniela Ortiz, Eugene Rogers, Thomas B. Shea. (2005) Monitoring thiobarbituric acid-reactive substances (TBARs) as an assay for oxidative damage in neuronal cultures and central nervous system. Journal of Neuroscience Methods 141:2, 219-222
CrossRef304
S. M. Lippman, P. J. Goodman, E. A. Klein, H. L. Parnes, I. M. Thompson, A. R. Kristal, R. M. Santella, J. L. Probstfield, C. M. Moinpour, D. Albanes, P. R. Taylor, L. M. Minasian, A. Hoque, S. M. Thomas, J. J. Crowley, J. M. Gaziano, J. L. Stanford, E. D. Cook, N. E. Fleshner, M. M. Lieber, P. J. Walther, F. R. Khuri, D. D. Karp, G. G. Schwartz, L. G. Ford, C. A. Coltman. (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JNCI Journal of the National Cancer Institute 97:2, 94-102
CrossRef305
Angelo Azzi, Regina Brigelius-Floh
, Frank Kelly, John K. Lodge, Nesrin
CrossRef306
Howard H Feldman, Bart Van Baelen, Shane M Kavanagh, Koen E. L Torfs. (2005) Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease. Alzheimer Disease & Associated Disorders 19:1, 29-36
CrossRef307
Colleen J. Maxwell, Matthew S. Hicks, David B. Hogan, Jenny Basran, Erika M. Ebly. (2005) Supplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia. Dementia and Geriatric Cognitive Disorders 20:1, 45-51
CrossRef308
Carlo Caltagirone, Angelo Bianchetti, Monica Di Luca, Patrizia Mecocci, Alessandro Padovani, Elvezio Pirfo, Pierluigi Scapicchio, Umberto Senin, Marco Trabucchi, Massimo Musicco. (2005) Guidelines for the Treatment of Alzheimer??s Disease from the Italian Association of Psychogeriatrics. Drugs & Aging 22:Suppl 1, 1???26
CrossRef309
John B. Standridge. (2005) Current Status and Future Promise of Pharmacotherapeutic Strategies for Alzheimer??s Disease. Journal of the American Medical Directors Association 6:3, 194???199
CrossRef310
Isabella Dalle-Donne, Andrea Scaloni, Daniela Giustarini, Eleonora Cavarra, Gianluca Tell, Giuseppe Lungarella, Roberto Colombo, Ranieri Rossi, Aldo Milzani. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: The contribution of redox proteomics. Mass Spectrometry Reviews 24:1, 55-99
CrossRef311
Aminah Jatoi, Stephen P. Kahanic, Stephen Frytak, Paul Schaefer, Robert L. Foote, Jeff Sloan, Ronald C. Petersen. (2005) Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Supportive Care in Cancer 13:1, 66-69
CrossRef312
N.W. Milgram, E. Head, S.C. Zicker, C.J. Ikeda-Douglas, H. Murphey, B. Muggenburg, C. Siwak, D. Tapp, C.W. Cotman. (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiology of Aging 26:1, 77-90
CrossRef313
R BULLOCK. (2005) Mild cognitive impairment. Psychiatry 4:1, 64-66
CrossRef314
Izumi Maezawa, Lee-Way Jin, Randall L. Woltjer, Nobuyo Maeda, George M. Martin, Thomas J. Montine, Kathleen S. Montine. (2004) Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. Journal of Neurochemistry 91:6, 1312-1321
CrossRef315
ANATOL KONTUSH, SVETLANA SCHEKATOLINA. (2004) Vitamin E in Neurodegenerative Disorders: Alzheimer's Disease. Annals of the New York Academy of Sciences 1031:1, 249-262
CrossRef316
Beatriz Martínez Villayandre, Miguel Angel Paniagua, Arsenio Fernández-López, Miguel Angel Chinchetru, Pedro Calvo. (2004) Effect of vitamin E treatment on N-methyl-d-aspartate receptor at different ages in the rat brain. Brain Research 1028:2, 148-155
CrossRef317
Fumitaka Osakada, Asami Hashino, Toshiaki Kume, Hiroshi Katsuki, Shuji Kaneko, Akinori Akaike. (2004) α-Tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 47:6, 904-915
CrossRef318
James A. Bourgeois, Donald M. Hilty, Celia H. Chang, Mark A. Wineinger, Mark E. Servis. (2004) Poststroke neuropsychiatric illness: An integrated approach to diagnosis and management. Current Treatment Options in Neurology 6:5, 403-420
CrossRef319
Anatol Kontush. (2004) Apolipoprotein Aβ: Black Sheep in a Good Family. Brain Pathology 14:4, 433-447
CrossRef320
José A Luchsinger, Richard Mayeux. (2004) Dietary factors and Alzheimer's disease. The Lancet Neurology 3:10, 579-587
CrossRef321
Jodi R. Godfrey. (2004) Toward Optimal Health: The Experts Discuss Memory Loss in Aging Women. Journal of Women's Health 13:8, 856-862
CrossRef322
M. Manders, L. C. P. G. M. de Groot, W. A. van Staveren, W. Wouters-Wesseling, A. J. M. J. Mulders, J. M. G. A. Schols, W. H. L. Hoefnagels. (2004) Effectiveness of Nutritional Supplements on Cognitive Functioning in Elderly Persons: A Systematic Review. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:10, M1041-M1049
CrossRef323
Elizabeth I. Majeski, Colin E. Widener, Jan Basile. (2004) Hypertension and dementia: Does blood pressure control favorably affect cognition?. Current Hypertension Reports 6:5, 357-362
CrossRef324
Martin Phys Farlow. (2004) Utilizing combination therapy in the treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics 4:5, 799-808
CrossRef325
Constantine G. Lyketsos, William E. Reichman, Paul Kershaw, Young Zhu. (2004) Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. American Journal of Geriatric Psychiatry 12:5, 473-482
CrossRef326
Kamesh Ayasolla, Mushfiquddin Khan, Avtar K Singh, Inderjit Singh. (2004) Inflammatory mediator and β-amyloid (25–35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology and Medicine 37:3, 325-338
CrossRef327
Yi Long Ma, Margaret E. Rice, Mei Lan Chao, Patricia M. Rivera, Huiwen W. Zhao, Austin P. Ross, Xiongwei Zhu, Mark A. Smith, Kelly L. Drew. (2004) Ascorbate distribution during hibernation is independent of ascorbate redox state. Free Radical Biology and Medicine 37:4, 511-520
CrossRef328
George Bartzokis, David Sultzer, Po H Lu, Keith H Nuechterlein, Jim Mintz, Jeffrey L Cummings. (2004) Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease. Neurobiology of Aging 25:7, 843-851
CrossRef329
Manfred Eggersdorfer, David Burdick, Regina Goralczyk, Daniel Raederstorff, Christoph Riegger, Wolfgang Schalch, Elisabeth Stöcklin, Peter Weber, Werner Bonrath. 2004. Nutraceuticals. .
CrossRef330
Wood, Alastair J.J., , Cummings, Jeffrey L., . (2004) Alzheimer's Disease. New England Journal of Medicine 351:1, 56-67
Full Text331
Julie K Andersen. (2004) Oxidative stress in neurodegeneration: cause or consequence?. Nature Reviews Neuroscience 10:7, S18-S25
CrossRef332
P. Mecocci, E. Mariani, V. Cornacchiola, M.C. Polidori. (2004) Antioxidants for the treatment of mild cognitive impairment. Neurological Research 26:5, 598-602
CrossRef333
A. D. Dangour, V. L. Sibson, A. E. Fletcher. (2004) Hormones and Supplements: Do They Work?: Micronutrient Supplementation in Later Life: Limited Evidence for Benefit. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:7, B659-B673
CrossRef334
Agnes A.S. Takeda, Juliana I. dos Santos, Silvana Marcussi, Lucas B. Silveira, Andreimar M. Soares, Marcos R.M. Fontes. (2004) Crystallization and preliminary X-ray diffraction analysis of an acidic phospholipase A2 complexed with p-bromophenacyl bromide and α-tocopherol inhibitors at 1.9- and 1.45-Å resolution. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1699:1-2, 281-284
CrossRef335
Teresa Kowalik-Jankowska, Monika Ruta, Kornelia Wiśniewska, Leszek Łankiewicz, Marcin Dyba. (2004) Products of Cu(II)-catalyzed oxidation in the presence of hydrogen peroxide of the 1–10, 1–16 fragments of human and mouse β-amyloid peptide. Journal of Inorganic Biochemistry 98:6, 940-950
CrossRef336
Nathalie Sumien, Kevin R Heinrich, Rajindar S Sohal, Michael J Forster. (2004) Short-term vitamin E intake fails to improve cognitive or psychomotor performance of aged mice. Free Radical Biology and Medicine 36:11, 1424-1433
CrossRef337
Taro Yamashita, Yukio Ando, Masaaki Nakamura, Konen Obayashi, Hisayasu Terazaki, Katsuki Haraoka, Sun Xu Guo, Mitsuharu Ueda, Makoto Uchino. (2004) Inhibitory effect of α-tocopherol on methylmercury-induced oxidative steress. Environmental Health and Preventive Medicine 9:3, 111-117
CrossRef338
Norton W. Milgram, Elizabeth Head, Steven C. Zicker, Candace Ikeda-Douglas, Heather Murphey, Bruce A. Muggenberg, Christina T. Siwak, P. Dwight Tapp, Stephen R. Lowry, Carl W. Cotman. (2004) Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Experimental Gerontology 39:5, 753-765
CrossRef339
Kathy Abascal, Eric Yarnell. (2004) Alzheimer's Disease: Part 2—A Botanical Treatment Plan. Alternative and Complementary Therapies 10:2, 67-72
CrossRef340
Janice E. Maras, Odilia I. Bermudez, Ning Qiao, Peter J. Bakun, Esther L. Boody-Alter, Katherine L. Tucker. (2004) Intake of α-tocopherol is limited among US adults. Journal of the American Dietetic Association 104:4, 567-575
CrossRef341
Gary L. Wenk, Kristin McGann-Gramling, Beatrice Hauss-Wegrzyniak, Daniela Ronchetti, Raffaella Maucci, Susanna Rosi, Laura Gasparini, Ennio Ongini. (2004) Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. Journal of Neurochemistry 89:2, 484-493
CrossRef342
Michael C. Irizarry. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRX 1:2, 226-234
CrossRef343
Xiongwei Zhu, Arun K Raina, George Perry, Mark A Smith. (2004) Alzheimer's disease: the two-hit hypothesis. The Lancet Neurology 3:4, 219-226
CrossRef344
Rebecca Costello, Judith Finkelstein, Leila Saldanha, Michelle Dell'Orto. (2004) Executive Summary: Conference on Dietary Supplement Use in the Elderly - Proceedings of the Conference Held January 14-15, 2003, Natcher Auditorium, National Institutes of Health, Bethesda, MD. Nutrition Reviews 62:4, 160-175
CrossRef345
XUDONG HUANG, ROBERT D. MOIR, RUDOLPH E. TANZI, ASHLEY I. BUSH, JACK T. ROGERS. (2004) Redox-Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology. Annals of the New York Academy of Sciences 1012:1, 153-163
CrossRef346
Susan D. Shenkin, Martha C. Whiteman, Alison Pattie, Ian J. Deary. (2004) Continued concern about nutritional supplements and cognitive function in the elderly. Nutrition 20:3, 336
CrossRef347
Xiongwei Zhu, Arun K. Raina, Hyoung-gon Lee, Gemma Casadesus, Mark A. Smith, George Perry. (2004) Oxidative stress signalling in Alzheimer's disease. Brain Research 1000:1-2, 32-39
CrossRef348
Laibaik Park, Josef Anrather, Colleen Forster, Ken Kazama, George A. Carlson, Costantino Iadecola. (2004) A??-Induced Vascular Oxidative Stress and Attenuation of Functional Hyperemia in Mouse Somatosensory Cortex. Journal of Cerebral Blood Flow & Metabolism334-342
CrossRef349
Janet Bryan. (2004) Mechanisms and evidence for the role of nutrition in cognitive ageing. Ageing International 29:1, 28-45
CrossRef350
Ann Marie Hake, Martin R Farlow. (2004) On the horizon: pathways for drug development in Alzheimer's disease. Clinics in Geriatric Medicine 20:1, 141-152
CrossRef351
Garth E. Ringheim, Katherine Conant. (2004) Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). Journal of Neuroimmunology 147:1-2, 43-49
CrossRef352
Agnes S. Chan, Mei-Chun Cheung, Stephen C. Law, John H. Chan. (2004) Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100:2, 398-404
CrossRef353
Beate Schmitt, Tanja Bernhardt, Hans-Juergen Moeller, Isabella Heuser, Lutz Fr??lich. (2004) Combination Therapy in Alzheimer???s Disease. CNS Drugs 18:13, 827-844
CrossRef354
Frank M. Longo, Stephen M. Massa. (2004) Neuroprotective strategies in Alzheimer’s disease. NeuroRX 1:1, 117-127
CrossRef355
Eiji Takeda, Junji Terao, Yutaka Nakaya, Ken-ichi Miyamoto, Yoshinobu Baba, Hiroshi Chuman, Ryuji Kaji, Tetsuro Ohmori, Kazuhito Rokutan. (2004) Stress control and human nutrition. The Journal of Medical Investigation 51:3,4, 139-145
CrossRef356
Michael C. Irizarry. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRX 1:2, 226
CrossRef357
Anna Rita Fetoni, Bruno Sergi, Aldo Ferraresi, Gaetano Paludetti, Diana Troiani. (2004) α-Tocopherol protective effects on gentamicin ototoxicity: an experimental study. International Journal of Audiology 43:3, 166-171
CrossRef358
Nathaniel G N Milton. (2004) Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease. Drugs & Aging 21:2, 81-100
CrossRef359
Rafael Blesa. (2004) Noncognitive Symptoms and Long-Term Treatment Expectations for Alzheimer Disease. Alzheimer Disease & Associated Disorders 18, S9-S16
CrossRef360
Karen Berman, Henry Brodaty. (2004) Tocopherol (Vitamin E) in Alzheimer???s Disease and Other Neurodegenerative Disorders. CNS Drugs 18:12, 807-825
CrossRef361
Frank M. Longo, Stephen M. Massa. (2004) Neuroprotective strategies in Alzheimer’s disease. NeuroRX 1:1, 117
CrossRef362
Kenneth Hensley, Elaine J. Benaksas, Roberto Bolli, Philip Comp, Paula Grammas, Ladan Hamdheydari, Shenyun Mou, Quentin N. Pye, Marcus F. Stoddard, Gemma Wallis, Kelly S. Williamson, Melinda West, William J. Wechter, Robert A. Floyd. (2004) New perspectives on vitamin E: γ-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radical Biology and Medicine 36:1, 1-15
CrossRef363
Mark Noble. (2004) The possible role of myelin destruction as a precipitating event in Alzheimer’s disease. Neurobiology of Aging 25:1, 25-31
CrossRef364
J. Emerit, M. Edeas, F. Bricaire. (2004) Neurodegenerative diseases and oxidative stress. Biomedicine & Pharmacotherapy 58:1, 39-46
CrossRef365
Anders Wimo. (2004) Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease. Drugs & Aging 21:5, 279-295
CrossRef366
Josef Marksteiner, Reinhold Schmidt. (2004) Treatment Strategies in Alzheimer???s Disease with a Focus on Early Pharmacological Interventions. Drugs & Aging 21:7, 415-426
CrossRef367
Kazuo YAMAGATA, Shizuko ICHINOSE, Motoki TAGAMI. (2004) Amlodipine and Carvedilol Prevent Cytotoxicity in Cortical Neurons Isolated from Stroke-Prone Spontaneously Hypertensive Rats. Hypertension Research 27:4, 271-282
CrossRef368
Eric E. Adelman, Jason H.T. Karlawish. (2003) Ignoring the Controversies: Newspaper Reports on Alzheimer's Disease Treatments. Journal of the American Geriatrics Society 51:12, 1821-1822
CrossRef369
Carla Pettenati, Roberta Annicchiarico, Carlo Caltagirone. (2003) Clinical pharmacology of anti-Alzheimer drugs. Fundamental & Clinical Pharmacology 17:6, 659-672
CrossRef370
Nick Lane. (2003) A unifying view of ageing and disease: the double-agent theory. Journal of Theoretical Biology 225:4, 531-540
CrossRef371
R.I Henkin, J.D Hoetker. (2003) Deficient dietary intake of vitamin E in patients with taste and smell dysfunctions:. Nutrition 19:11-12, 1013-1021
CrossRef372
Ranjit Kumar Chandra. (2003) Can nutrient supplements improve functional outcome in the elderly?. Nutrition 19:11-12, 978-980
CrossRef373
Robert W Stackman, Felix Eckenstein, Balz Frei, Doris Kulhanek, Jessica Nowlin, Joseph F Quinn. (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology 184:1, 510-520
CrossRef374
Seth Roberts, Saul Sternberg. (2003) Do nutritional supplements improve cognitive function in the elderly?. Nutrition 19:11-12, 976-978
CrossRef375
Mark A. McDaniel, Steven F. Maier, Gilles O. Einstein. (2003) “Brain-specific” nutrients: a memory cure?. Nutrition 19:11-12, 957-975
CrossRef376
Renata Franzon, Marcelo L. Lamers, Francieli M. Stefanello, Clóvis M.D. Wannmacher, Moacir Wajner, Angela T.S. Wyse. (2003) Evidence that oxidative stress is involved in the inhibitory effect of proline on Na+,K+-ATPase activity in synaptic plasma membrane of rat hippocampus. International Journal of Developmental Neuroscience 21:6, 303-307
CrossRef377
Jason H. T. Karlawish, David J. Casarett, Bryan D. James, Tom Tenhave, Christopher M. Clark, David A. Asch. (2003) Why Would Caregivers Not Want to Treat Their Relative's Alzheimer's Disease?. Journal of the American Geriatrics Society 51:10, 1391-1397
CrossRef378
John C. Morris. (2003) Dementia Update 2003. Alzheimer Disease & Associated Disorders 17:4, 245-258
CrossRef379
Dun-Xian Tan, Lucien C Manchester, Rosa Sainz, Juan C Mayo, Frederick L Alvares, Russel J Reiter. (2003) Antioxidant strategies in protection against neurodegenerative disorders. Expert Opinion on Therapeutic Patents 13:10, 1513-1543
CrossRef380
Tomasz Sobow, Iwona Kloszewska. (2003) Donepezil Plus Vitamin E as a Treatment in Alzheimer Disease. Alzheimer Disease & Associated Disorders 17:4, 244
CrossRef381
D. S. Knopman, B. F. Boeve, R. C. Petersen. (2003) Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. Mayo Clinic Proceedings 78:10, 1290-1308
CrossRef382
Kawas, Claudia H., . (2003) Early Alzheimer's Disease. New England Journal of Medicine 349:11, 1056-1063
Full Text383
L. J. Whalley, H. C. Fox, H. A. Lemmon, S. J. Duthie, A. R. Collins, H. Peace, J. M. Starr, I. J. Deary. (2003) Dietary supplement use in old age: associations with childhood IQ, current cognition and health. International Journal of Geriatric Psychiatry 18:9, 769-776
CrossRef384
David Mantle, Victor Preedy, Richard Wilkins. 2003. Free radicals as toxic agents. , 331-349.
CrossRef385
Quan Liu, Arun K. Raina, Mark A. Smith, Lawrence M. Sayre, George Perry. (2003) Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Molecular Aspects of Medicine 24:4-5, 305-313
CrossRef386
Steven DeKosky. (2003) Early Intervention Is Key to Successful Management of Alzheimer Disease. Alzheimer Disease & Associated Disorders 17:SUPPLEMENT 4, S99-S104
CrossRef387
Francine Grodstein, Jennifer Chen, Susan E. Hankinson. (2003) Cataract Extraction and Cognitive Function in Older Women. Epidemiology 14:4, 493-497
CrossRef388
Pierre N. Tariot, Howard J. Federoff. (2003) Current Treatment for Alzheimer Disease and Future Prospects. Alzheimer Disease & Associated Disorders 17:SUPPLEMENT 4, S105-S113
CrossRef389
Roger Bullock, Gerry Hammond. (2003) Realistic Expectations: The Management of Severe Alzheimer Disease. Alzheimer Disease & Associated Disorders 17:SUPPLEMENT 3, S80-S85
CrossRef390
Marta Weinstock, Elena Gorodetsky, Tatyana Poltyrev, Aviva Gross, Yotam Sagi, Moussa Youdim. (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27:4, 555-561
CrossRef391
David S. Geldmacher. (2003) Alzheimer's Disease: Current Pharmacotherapy in the Context of Patient and Family Needs. Journal of the American Geriatrics Society 51:5s2, S289-S295
CrossRef392
Thomas B. Shea, Eugene Rogers, David Ashline, Daniela Ortiz, Min-Shyan Sheu. (2003) Quantification of antioxidant activity in brain tissue homogenates using the ‘total equivalent antioxidant capacity’. Journal of Neuroscience Methods 125:1-2, 55-58
CrossRef393
Bennett P. Leifer. (2003) Early Diagnosis of Alzheimer's Disease: Clinical and Economic Benefits. Journal of the American Geriatrics Society 51:5s2, S281-S288
CrossRef394
Steven T. DeKosky. (2003) Pathology and Pathways of Alzheimer's Disease with an Update on New Developments in Treatment. Journal of the American Geriatrics Society 51:5s2, S314-S320
CrossRef395
André Boland, Jean Gérardy, Danielle Mossay, Vincent Seutin. (2003) Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death. European Journal of Pharmacology 466:1-2, 21-30
CrossRef396
Leon J. Thal. (2003) Therapeutics and Mild Cognitive Impairment. Alzheimer Disease & Associated Disorders 17:Sup 2, S69-S71
CrossRef397
Alan D. Dangour, Suraiya J. Ismail. (2003) Editorial: Ageing and nutrition in developing countries. Tropical Medicine and International Health 8:4, 287-289
CrossRef398
Emily T. Klatte, Douglas W. Scharre, Haikady N. Nagaraja, Rebecca A. Davis, David Q. Beversdorf. (2003) Combination Therapy of Donepezil and Vitamin E in Alzheimer Disease. Alzheimer Disease & Associated Disorders 17:2, 113-116
CrossRef399
W. A. Banks, J. E. Morley. (2003) Memories Are Made of This: Recent Advances in Understanding Cognitive Impairments and Dementia. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58:4, M314-M321
CrossRef400
G. T. Grossberg, A. K. Desai. (2003) Management of Alzheimer's Disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 58:4, M331-M353
CrossRef401
David Knopman. (2003) Pharmacotherapy for Alzheimer's Disease: 2002. Clinical Neuropharmacology 26:2, 93-101
CrossRef402
Fumitaka Osakada, Asami Hashino, Toshiaki Kume, Hiroshi Katsuki, Shuji Kaneko, Akinori Akaike. (2003) Neuroprotective effects of α-tocopherol on oxidative stress in rat striatal cultures. European Journal of Pharmacology 465:1-2, 15-22
CrossRef403
Subbiah Pugazhenthi, Albina Nesterova, Purevsuren Jambal, Gerald Audesirk, Marcey Kern, Leigh Cabell, Eva Eves, Marsha R. Rosner, Linda M. Boxer, Jane E.-B. Reusch. (2003) Oxidative stress-mediated down-regulation of bcl-2 promoter in hippocampal neurons. Journal of Neurochemistry 84:5, 982-996
CrossRef404
Anders Wimo, Bengt Winblad. (2003) Pharmacoeconomics of mild cognitive impairment. Acta Neurologica Scandinavica 107:s179, 94-99
CrossRef405
Vesna Jelic, Bengt Winblad. (2003) Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurologica Scandinavica 107:s179, 83-93
CrossRef406
Ishwarlal Jialal, Sridevi Devaraj. 2003. Prospective Vitamin E Clinical Trials. .
CrossRef407
Ute Obermuller-Jevic b, Lester Packer a. 2003. Vitamin E in Disease Prevention and Therapy. .
CrossRef408
Jacqueline Birks, Leon Flicker, Jacqueline Birks. 2003. Selegiline for Alzheimer's disease. .
CrossRef409
Harry Ischiropoulos, Joseph S. Beckman. (2003) Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?. Journal of Clinical Investigation 111:2, 163-169
CrossRef410
Math P. Cuajungco, Kyle Y. Fagét. (2003) Zinc takes the center stage: its paradoxical role in Alzheimer’s disease. Brain Research Reviews 41:1, 44-56
CrossRef411
Sandra K. Pope, Valorie M. Shue, Cornelia Beck. (2003) W
ILL A HEALTHY LIFESTYLE HELP PREVENT ALZHEIMER'S DISEASE ?. Annual Review of Public Health 24:1, 111-132
CrossRef412
P. Clayton. 2003. Mood, cognitive function, nutritional and other supplements. , 21-37.
CrossRef413
D Allan Butterfield, Chava B Pocernich. (2003) The Glutamatergic System and Alzheimer???s Disease. CNS Drugs 17:9, 641-652
CrossRef414
Leonidas H. Duntas, Jacques Orgiazzi. (2003) Vitamin E and thyroid disease: A potential link that kindles hope. BioFactors 19:3-4, 131-135
CrossRef415
Richard Mayeux. 2003. Alzheimer's Disease, Epidemiology. , 96-102.
CrossRef416
(2002) Preface. Advanced Drug Delivery Reviews 54:12, 1533-1537
CrossRef417
Amy H Moore, M.K O’Banion. (2002) Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease. Advanced Drug Delivery Reviews 54:12, 1627-1656
CrossRef418
K.L Drew, Ø Tøien, P.M Rivera, M.A Smith, George Perry, M.E Rice. (2002) Role of the antioxidant ascorbate in hibernation and warming from hibernation. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 133:4, 483-492
CrossRef419
Karen E Charlton. (2002) Eating well: ageing gracefully!. Asia Pacific Journal of Clinical Nutrition 11:s3, S607-S617
CrossRef420
Bruce Teter, J. Wesson Ashford. (2002) Neuroplasticity in Alzheimer's disease. Journal of Neuroscience Research 70:3, 402-437
CrossRef421
Lon S. Schneider, Pierre N. Tariot, Constantine G. Lyketsos, Karen S. Dagerman, Kenneth L. Davis, Sonia Davis, John K. Hsiao, Dilip V. Jeste, Ira R. Katz, Jason T. Olin, Bruce G. Pollock, Peter V. Rabins, Robert A. Rosenheck, Gary W. Small, Barry Lebowitz, Jeffery A. Lieberman. (2002) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). American Journal of Geriatric Psychiatry 9:4, 346-360
CrossRef422
John P Blass. (2002) Alzheimer’s disease and Alzheimer’s dementia: distinct but overlapping entities. Neurobiology of Aging 23:6, 1077-1084
CrossRef423
J. C. TORRE. (2002) Vascular Basis of Alzheimer's Pathogenesis. Annals of the New York Academy of Sciences 977:1, 196-215
CrossRef424
Bart P.F. Rutten, Harry W.M. Steinbusch, Hubert Korr, Christoph Schmitz. (2002) Antioxidants and Alzheimerʼs disease: from bench to bedside (and back again). Current Opinion in Clinical Nutrition and Metabolic Care 5:6, 645-651
CrossRef425
David Bebbington, Claire E Dawson, Suneel Gaur, John Spencer. (2002) Prodrug and covalent linker strategies for the solubilization of dual-Action antioxidants/Iron chelators. Bioorganic & Medicinal Chemistry Letters 12:22, 3297-3300
CrossRef426
Mary Sano. (2002) Prevention of Alzheimer’s disease: Where we stand. Current Neurology and Neuroscience Reports 2:5, 392-399
CrossRef427
Brian Cooper. (2002) Thinking preventively about dementia: a review. International Journal of Geriatric Psychiatry 17:10, 895-906
CrossRef428
Bernd Moosmann, Christian Behl. (2002) Antioxidants as treatment for neurodegenerative disorders. Expert Opinion on Investigational Drugs 11:10, 1407-1435
CrossRef429
Gail Shor-Posner, Robert Lecusay, Guillermo Morales, Adriana Campa, Maria-Jose Miguez-Burbano. (2002) Neuroprotection in HIV-Positive Drug Users: Implications for Antioxidant Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S84-S88
CrossRef430
Anne Perrault, Christina Wolfson, Mary Egan, Kenneth Rockwood, David B. Hogan. (2002) Prognostic Factors for Functional Independence in Older Adults With Mild Dementia: Results From the Canadian Study of Health and Aging. Alzheimer Disease & Associated Disorders 16:4, 239-247
CrossRef431
A. Fisher, J. E. Morley. (2002) Editorial: Antiaging Medicine: The Good, the Bad, and the Ugly. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:10, M636-M639
CrossRef432
Lorna Schumann, Jennifer Hagerty Lingler, Daniel I. Kaufer. (2002) Cognitive and Motor Symptoms in Dementia: Focus on Dementia with Lewy Bodies. Journal of the American Academy of Nurse Practitioners 14:9, 398-407
CrossRef433
Alan M. Palmer. (2002) Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends in Pharmacological Sciences 23:9, 426-433
CrossRef434
Pedro Montilla-López, M.Carmen Muñoz-Águeda, Montserrat Feijóo López, Juan R Muñoz-Castañeda, Inmaculada Bujalance-Arenas, Isaac Túnez-Fiñana. (2002) Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. European Journal of Pharmacology 451:3, 237-243
CrossRef435
A. Pieroni, V. Janiak, C. M. D
CrossRef436
Peter Hedera, R.Scott Turner. (2002) Inherited dementias. Neurologic Clinics 20:3, 779-808
CrossRef437
Manh Hung Tran, Kiyofumi Yamada, Toshitaka Nabeshima. (2002) Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits: a minireview. Peptides 23:7, 1271-1283
CrossRef438
Jes
CrossRef439
S
CrossRef440
Paul S. Aisen. (2002) Development of antiinflammatory therapy for Alzheimer's disease. Drug Development Research 56:3, 421-427
CrossRef441
Dana Perkins. (2002) Targeting apoptosis in neurological disease using the herpes simplex virus. Journal of Cellular and Molecular Medicine 6:3, 341-356
CrossRef442
Miguel A Pappolla, Mark A Smith, Tara Bryant-Thomas, Nicolas Bazan, Suzana Petanceska, George Perry, Leon J Thal, Mary Sano, Lorenzo M Refolo. (2002) Cholesterol, oxidative stress, and Alzheimer’s disease: expanding the horizons of pathogenesis1 1This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine 33:2, 173-181
CrossRef443
Gerd Multhaup, Stefan Scheuermann, Andrea Schlicksupp, Andreas Simons, Markus Strauss, André Kemmling, Christian Oehler, Roberto Cappai, Rüdiger Pipkorn, Thomas A Bayer. (2002) Possible mechanisms of APP-mediated oxidative stress in Alzheimer’s disease1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine 33:1, 45-51
CrossRef444
C.E. Teunissen, J. de Vente, H.W.M. Steinbusch, C. De Bruijn. (2002) Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiology of Aging 23:4, 485-508
CrossRef445
Todd E. Golde, Jason L. Eriksen, Sascha Weggen, Sarah A. Sagi, Edward H. Koo. (2002) Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Development Research 56:3, 415-420
CrossRef446
Marco Onofrj, Astrid Thomas, Anna Lisa Luciano, Diego Iacono, Andrea Di Rollo, Giordano D'Andreamatteo, Angelo Di Iorio. (2002) Donepezil Versus Vitamin E in Alzheimer's Disease Part 2: Mild Versus Moderate???Severe Alzheimer's Disease. Clinical Neuropharmacology 25:4, 207-215
CrossRef447
Elise A. Malecki, James R. Connor. (2002) The case for iron chelation and/or antioxidant therapy in Alzheimer's disease. Drug Development Research 56:3, 526-530
CrossRef448
John M. de Figueiredo. (2002) Methodological Aspects of Comparative Research in the Epidemiology of Alzheimer Disease. American Journal of Geriatric Psychiatry 10:4, 373-385
CrossRef449
Christian Behl, Bernd Moosmann. (2002) Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach2 2This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine 33:2, 182-191
CrossRef450
Thomas B Shea, Fatma J Ekinci, Daniela Ortiz, Maria Dawn-Linsley, Thomas O Wilson, Robert J Nicolosi. (2002) Efficacy of vitamin E, phosphatidyl choline, and pyruvate on buffering neuronal degeneration and oxidative stress in cultured cortical neurons and in central nervous tissue of apolipoprotein E-deficient mice. Free Radical Biology and Medicine 33:2, 276-282
CrossRef451
H. M. Fillit, R. N. Butler, A. W. O'Connell, M. S. Albert, J. E. Birren, C. W. Cotman, W. T. Greenough, P. E. Gold, A. F. Kramer, L. H. Kuller, T. T. Perls, B. G. Sahagan, T. Tully. (2002) Achieving and Maintaining Cognitive Vitality With Aging. Mayo Clinic Proceedings 77:7, 681-696
CrossRef452
Jennifer Drake, Jaroslaw Kanski, Sridhar Varadarajan, Maria Tsoras, D. Allan Butterfield. (2002) Elevation of brain glutathione by ?-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. Journal of Neuroscience Research 68:6, 776-784
CrossRef453
Benoit I. Giasson, Harry Ischiropoulos, Virginia M.-Y. Lee, John Q. Trojanowski. (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases1,2 11Guest Editors: Mark A. Smith and George Perry 22This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine 32:12, 1264-1275
CrossRef454
Sönke Arlt, Ulrike Beisiegel, Anatol Kontush. (2002) Lipid peroxidation in neurodegeneration: new insights into Alzheimerʼs disease. Current Opinion in Lipidology 13:3, 289-294
CrossRef455
Joshua Chodosh, David B. Reuben, Marilyn S. Albert, Teresa E. Seeman. (2002) Predicting Cognitive Impairment in High-Functioning Community-Dwelling Older Persons: MacArthur Studies of Successful Aging. Journal of the American Geriatrics Society 50:6, 1051-1060
CrossRef456
Christopher M. Filley. (2002) Drug Treatment of Alzheimer???s Disease. Primary Care Case Reviews 5:2, 77-85
CrossRef457
Michael Grundman, Patrick Delaney. (2002) Antioxidant strategies for Alzheimer's disease. Proceedings of the Nutrition Society 61:02, 191-202
CrossRef458
M.Flint Beal. (2002) Oxidatively modified proteins in aging and disease1,2 1Guest Editor: Earl Stadtman 2This article is part of a series of reviews on “Oxidatively Modified Proteins in Aging and Disease.” The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine 32:9, 797-803
CrossRef459
Philip D. Sloane, Sheryl Zimmerman, Chirayath Suchindran, Peter Reed, Lily Wang, Malaz Boustani, S. Sudha. (2002) T
HE PUBLIC HEALTH IMPACT OF ALZHEIMER'S DISEASE , 2000–2050: Potential Implication of Treatment Advances. Annual Review of Public Health 23:1, 213-231
CrossRef460
Lauren T Bonner, Elaine R Peskind. (2002) Pharmacologic treatments of dementia. Medical Clinics of North America 86:3, 657-674
CrossRef461
Mohsen Meydani. (2002) The Boyd Orr Lecture: Nutrition interventions in aging and age-associated disease. Proceedings of the Nutrition Society 61:02, 165-171
CrossRef462
R.K. Chandra. (2002) Response to comments of Shenkin et al. Nutrition 18:4, 365-366
CrossRef463
Georg Gr
CrossRef464
James C Anthony, John CS Breitner, Peter P Zandi. (2002) Is pharmacological prevention of Alzheimer's a realistic goal?. Expert Opinion on Pharmacotherapy 3:4, 365-380
CrossRef465
D. Gomez-Coronado, A. Entrala, J. J. Alvarez, H. Ortega, J. M. Olmos, M. Castro, A. Sastre, E. Herrera, M. A. Lasuncion. (2002) Influence of apolipoprotein E polymorphism on plasma vitamin A and vitamin E levels. European Journal of Clinical Investigation 32:4, 251-258
CrossRef466
KENICHI KITANI, CHIYOKO MINAMI, TAKAKO YAMAMOTO, SETSUKO KANAI, GWEN O. IVY, MARIA-CRISTINA CARRILLO. (2002) Pharmacological Interventions in Aging and Age-associated Disorders. Annals of the New York Academy of Sciences 959:1, 295-307
CrossRef467
DENHAM HARMAN. (2002) Alzheimer's Disease: Role of Aging in Pathogenesis. Annals of the New York Academy of Sciences 959:1, 384-395
CrossRef468
C. Behl, B. Moosmann. (2002) Oxidative Nerve Cell Death in Alzheimers Disease and Stroke: Antioxidants as Neuroprotective Compounds. Biological Chemistry 383:3-4, 521-536
CrossRef469
Kelly S. Williamson, S. Prasad Gabbita, Shenyun Mou, Melinda West, Quentin N. Pye, William R. Markesbery, Robert V. Cooney, Paula Grammas, Ulrich Reimann-Philipp, Robert A. Floyd, Kenneth Hensley. (2002) The Nitration Product 5-Nitro-γ-tocopherol Is Increased in the Alzheimer Brain. Nitric Oxide 6:2, 221-227
CrossRef470
G. K. Wilcock, J. Birks, A. Whitehead, Sir John Grimley Evans. (2002) The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. International Journal of Geriatric Psychiatry 17:2, 175-183
CrossRef471
Mark A Moyad. (2002) The placebo effect and randomized trials: analysis of alternative medicine. Urologic Clinics of North America 29:1, 135-155
CrossRef472
Sidney T. Bogardus, Emily Richardson, Paul K. Maciejewski, Evelyne Gahbauer, Sharon K. Inouye. (2002) Evaluation of a Guided Protocol for Quality Improvement in Identifying Common Geriatric Problems. Journal of the American Geriatrics Society 50:2, 328-335
CrossRef473
A Boland, J Gérardy, D Mossay, D Delapierre, V Seutin. (2002) Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition. British Journal of Pharmacology 135:3, 713-720
CrossRef474
Jean C. Shih. 2002. Monoamine Oxidases. .
CrossRef475
Cynthia M. Carlsson, Kristi Papcke-Benson, Molly Carnes, Patrick E. McBride, James H. Stein. (2002) Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults. Drugs & Aging 19:10, 793-805
CrossRef476
Xiao Qiu Xiao, Hai Yan Zhang, Xi Can Tang. (2002) Huperzine A attenuates amyloid ?-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. Journal of Neuroscience Research 67:1, 30-36
CrossRef477
B Topic, E Tani, K Tsiakitzis, P.N Kourounakis, E Dere, R.U Hasenöhrl, R Häcker, C.M Mattern, J.P Huston. (2002) Enhanced maze performance and reduced oxidative stress by combined extracts of zingiber officinale and ginkgo biloba in the aged rat. Neurobiology of Aging 23:1, 135-143
CrossRef478
Robyn Vesey, Jennifer M. Birrell, Clare Bolton, Ruth S. Chipperfield, Andrew D. Blackwell, Tom R. Dening, Barbara J. Sahakian. (2002) Cholinergic Nicotinic Systems in Alzheimer??s Disease. CNS Drugs 16:7, 485-500
CrossRef479
Tim Ibbotson, Karen L. Goa. (2002) Management of Alzheimer??s Disease. Disease Management and Health Outcomes 10:1, 41-54
CrossRef480
Willett, Walter C., Stampfer, Meir J., . (2001) What Vitamins Should I Be Taking, Doctor?. New England Journal of Medicine 345:25, 1819-1824
Full Text481
Tamara Egger, Astrid Hammer, Andrea Wintersperger, Daniel Goti, Ernst Malle, Wolfgang Sattler. (2001) Modulation of microglial superoxide production by α-tocopherol in vitro: attenuation of p67phox translocation by a protein phosphatase-dependent pathway. Journal of Neurochemistry 79:6, 1169-1182
CrossRef482
Carol A Scorer. (2001) Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. Drug Discovery Today 6:23, 1207-1219
CrossRef483
Martin R Farlow, Ann Marie Hake. (2001) New concepts in the drug therapy of Alzheimer’s disease. Expert Opinion on Pharmacotherapy 2:12, 1975-1983
CrossRef484
Zhi-Zhong Guan, Xiao Zhang, Malahat Mousavi, Jian-Ying Tian, Christina Unger, Agneta Nordberg. (2001) Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. Journal of Neuroscience Research 66:4, 551-558
CrossRef485
Bernd Moosmann, Thomas Skutella, Klaus Beyer, Christian Behl. (2001) Protective Activity of Aromatic Amines and Imines against Oxidative Nerve Cell Death. Biological Chemistry 382:11, 1601-1612
CrossRef486
W. Reynish, S. Andrieu, F. Nourhashemi, B. Vellas. (2001) Nutritional Factors and Alzheimer's Disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:11, M675-M680
CrossRef487
S Pruthi, T G Allison, D D Hensrud. (2001) Vitamin E supplementation in the prevention of coronary heart disease.. Mayo Clinic Proceedings 76:11, 1131-1136
CrossRef488
G Franklin Carl. 2001. Nutritional Therapies for Neurological and Psychiatric Disorders. .
CrossRef489
Allen Perelson, Leon Ellenbogen. 2001. Rationale for Use of Vitamin and Mineral Supplements. .
CrossRef490
Yuekui Li, Ling Liu, Steven W. Barger, Robert E. Mrak, W. Sue T. Griffin. (2001) Vitamin E suppression of microglial activation is neuroprotective. Journal of Neuroscience Research 66:2, 163-170
CrossRef491
Christy C. Tangney. (2001) Does vitamin E protect against cognitive changes as we age?. Nutrition 17:10, 806-808
CrossRef492
J. Knoll. (2001) Antiaging Compounds: (-)Deprenyl (Selegiline) and (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a Selective Highly Potent Enhancer of the Impulse Propagation Mediated Release of Catecholamines and Serotonin in the Brain. CNS Drug Reviews 7:3, 317-345
CrossRef493
Kelly L Drew, Margaret E Rice, Thomas B Kuhn, Mark A Smith. (2001) Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neurodegenerative diseases. Free Radical Biology and Medicine 31:5, 563-573
CrossRef494
Anders Wimo, Bengt Winblad. (2001) Health Economical Aspects of Alzheimer Disease and its Treatment. Psychogeriatrics 1:3, 189-193
CrossRef495
M. González-Gross, Ascensión Marcos, Klaus Pietrzik. (2001) Nutrition and cognitive impairment in the elderly. British Journal of Nutrition 86:03, 313
CrossRef496
Anatol Kontush, Ulrike Mann, Sönke Arlt, Amaar Ujeyl, Charlotte Lührs, Tomas Müller-Thomsen, Ulrike Beisiegel. (2001) Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer’s disease. Free Radical Biology and Medicine 31:3, 345-354
CrossRef497
Deborah B. Marin, Sean Flynn, Marlene Mare, Melinda Lantz, Ming-Ann Hsu, Max Laurans, Maria Paredes, Tricia Shreve, Gabrielle R. Zaklad, Richard C. Mohs. (2001) Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale. International Journal of Geriatric Psychiatry 16:8, 745-750
CrossRef498
Ira T. Lott, Elizabeth Head. (2001) Down syndrome and Alzheimer's disease: A link between development and aging. Mental Retardation and Developmental Disabilities Research Reviews 7:3, 172-178
CrossRef499
Mohsen Meydani. (2001) Antioxidants and Cognitive Function. Nutrition Reviews 59:8, S75-S82
CrossRef500
Roger Bullock. (2001) Drug treatment in dementia. Current Opinion in Psychiatry 14:4, 349-353
CrossRef501
Annlia Paganini-Hill, Linda J. Clark, Victor W. Henderson, Stanley J. Birge. (2001) Clock Drawing: Analysis in a Retirement Community. Journal of the American Geriatrics Society 49:7, 941-947
CrossRef502
Benjamin L. Hart. (2001) Effect of gonadectomy on subsequent development of age-related cognitive impairment in dogs. Journal of the American Veterinary Medical Association 219:1, 51-56
CrossRef503
M. Sampietro, L. Caputo, A. Casatta, M. Meregalli, A. Pellagatti, J. Tagliabue, G. Annoni, C. Vergani. (2001) The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease. Neurobiology of Aging 22:4, 563-568
CrossRef504
Jacqueline C. Neilson, Benjamin L. Hart, Kelly D. Cliff, William W. Ruehl. (2001) Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. Journal of the American Veterinary Medical Association 218:11, 1787-1791
CrossRef505
Linda J. Ball, Allison Ogden, Deepak Mandi, Stanley J. Birge. (2001) The Validation of a Mailed Health Survey for Screening of Dementia of the Alzheimer's Type. Journal of the American Geriatrics Society 49:6, 798-802
CrossRef506
Naji Tabet, David Mantle, Zuzana Walker, Martin Orrell. (2001) Dietary and endogenous antioxidants in dementia. International Journal of Geriatric Psychiatry 16:6, 639-641
CrossRef507
Yossi Gilgun-Sherki, Eldad Melamed, Daniel Offen. (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:8, 959-975
CrossRef508
Maria Brzyska, Andrzej Bacia, Danek Elbaum. (2001) Oxidative and hydrolytic properties of
CrossRef509
Stefan Weber, Lester Packer. 2001. The Role of Vitamin E in the Emerging Field of Nutraceuticals. .
CrossRef510
Suzanne Holroyd, Michael L Shepherd. (2001) Alzheimer's Disease. Survey of Ophthalmology 45:6, 516-524
CrossRef511
Wojciech Danysz. (2001) Neurotoxicity as a Mechanism for Neurodegenerative Disorders: Basic and Clinical Aspects. Expert Opinion on Investigational Drugs 10:5, 985-989
CrossRef512
Judith Morris, Ladislav Volicer. (2001) Nutritional Management of Individuals with Alzheimer's Disease and Other Progressive Dementias. Nutrition in Clinical Care 4:3, 148-155
CrossRef513
Murray A. Raskind, Elaine R. Peskind. (2001) ALZHEIMER'S DISEASE AND RELATED DISORDERS. Medical Clinics of North America 85:3, 803-817
CrossRef514
E Reiman. (2001) Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clinical Neuroscience Research 1:3, 194-206
CrossRef515
Ji-Jing Yan, Jae-Young Cho, Hee-Sung Kim, Kyoung-Li Kim, Jun-Sub Jung, Sung-Oh Huh, Hong-Won Suh, Yung-Hi Kim, Dong-Keun Song. (2001) Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. British Journal of Pharmacology 133:1, 89-96
CrossRef516
Anne-Sophie Nicolas, L. Fati Nourhashemi, Dominique Lanzmann-Petithory, Bruno Vellas. (2001) Nutrition and Cognitive Function. Nutrition in Clinical Care 4:3, 156-167
CrossRef517
PLS Chan, NHG Holford. (2001) D
RUG TREATMENT EFFECTS ON DISEASE PROGRESSION . Annual Review of Pharmacology and Toxicology 41:1, 625-659
CrossRef518
Bruce N. Ames. (2001) DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 475:1-2, 7-20
CrossRef519
Kenichi Kitani, Chiyoko Minami, Takako Yamamoto, Wakako Maruyama, Setsuko Kanai, Gwen O. Ivy, Maria-Cristina Carrillo. (2001) Do Antioxidant Strategies Work against Aging and Age-associated Disorders?. Annals of the New York Academy of Sciences 928:1, 248-260
CrossRef520
Shuji Gamoh, Michio Hashimoto, Shahdat Hossain, Sumio Masumura. (2001) Chronic Administration Of Docosahexaenoic Acid Improves The Performance Of Radial Arm Maze Task In Aged Rats. Clinical and Experimental Pharmacology and Physiology 28:4, 266-270
CrossRef521
Mohsen Meydani. (2001) Nutrition Interventions in Aging and Age-Associated Disease. Annals of the New York Academy of Sciences 928:1, 226-235
CrossRef522
A Jon Stoessl. (2001) Antisense strategies for the treatment of neurological disease. Expert Opinion on Therapeutic Patents 11:4, 547-562
CrossRef523
John J Sramek, Amy E Veroff, Neal R Cutler. (2001) The status of ongoing trials for mild cognitive impairment. Expert Opinion on Investigational Drugs 10:4, 741-752
CrossRef524
Antonio Contestabile. (2001) Antioxidant strategies for neurodegenerative diseases. Expert Opinion on Therapeutic Patents 11:4, 573-585
CrossRef525
Bernhard HJ Juurlink. (2001) Therapeutic potential of dietary phase 2 enzyme inducers in ameliorating diseases that have an underlying inflammatory component. Canadian Journal of Physiology and Pharmacology 79:3, 266-282
CrossRef526
R. Scott Turner. (2001) Alzheimer’s Disease in Man and Transgenic Mice. The American Journal of Pathology 158:3, 797-801
CrossRef527
Jeffrey L. Cummings, Vorapun Senanarong. (2001) Geriatric Neuropsychopharmacology: Unmet Needs. Psychogeriatrics 1:1, 14-26
CrossRef528
Ishwarlal Jialal, Maret Traber, Sridevi Devaraj. (2001) Is there a vitamin E paradox?. Current Opinion in Lipidology 12:1, 49-53
CrossRef529
Christopher H. Dyck. (2001) Neuroimaging in alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 3:1, 13-19
CrossRef530
GEORGE T. CAPONE. (2001) Down Syndrome: Advances in Molecular Biology and the Neurosciences. Journal of Developmental & Behavioral Pediatrics 22:1, 40-59
CrossRef531
Julian N Trollor, Michael J Valenzuela. (2001) Brain ageing in the new millennium. Australian and New Zealand Journal of Psychiatry 35:6, 788-805
CrossRef532
Michiel E. Hemels, Krista L. Lanctot, Michael Iskedjian, Thomas R. Einarson. (2001) Clinical and Economic Factors in the Treatment of Behavioural and Psychological Symptoms of Dementia. Drugs & Aging 18:7, 527-550
CrossRef533
Neal R. Cutler, John J. Sramek. (2001) Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25:1, 27-57
CrossRef534
D Selkoe. (2001) Presenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease. Clinical Neuroscience Research 1:1-2, 91-103
CrossRef535
Julianne S. Collins, Rodney T. Perry, Bracie Watson, Lindy E. Harrell, Ronald T. Acton, Deborah Blacker, Marilyn S. Albert, Rudolph E. Tanzi, Susan S. Bassett, Melvin G. McInnis, R. Duncan Campbell, Rodney C.P. Go. (2000) Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: The NIMH Alzheimer disease genetics initiative. American Journal of Medical Genetics 96:6, 823-830
CrossRef536
Soledad Miranda, Carlos Opazo, Luis F Larrondo, Francisco J Muñoz, Francisca Ruiz, Federico Leighton, Nibaldo C Inestrosa. (2000) The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease. Progress in Neurobiology 62:6, 633-648
CrossRef537
G.J. Brewer. (2000) Neuronal plasticity and stressor toxicity during aging. Experimental Gerontology 35:9-10, 1165-1183
CrossRef538
Mareyuki Takahashi, Shuji Kojima, Kiyonori Yamaoka, Etsuo Niki. (2000) Prevention of Type I Diabetes by Low-Dose Gamma Irradiation in NOD Mice. Radiation Research 154:6, 680-685
CrossRef539
Stephen J Peroutka, Darlene M Dreon. (2000) The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation. European Journal of Pharmacology 410:2-3, 161-163
CrossRef540
Roger M. Nitsch, Meihua Deng, Marsha Tennis, David Schoenfeld, John H. Growdon. (2000) The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology 48:6, 913-918
CrossRef541
M. FLINT BEAL. (2000) Oxidative Metabolism. Annals of the New York Academy of Sciences 924:1, 164-169
CrossRef542
Michael Grundman, Leon J. Thal. (2000) TREATMENT OF ALZHEIMER'S DISEASE. Neurologic Clinics 18:4, 807-827
CrossRef543
Kiyofumi Yamada, Toshitaka Nabeshima. (2000) Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacology & Therapeutics 88:2, 93-113
CrossRef544
Walter A. Kukull, Mary Ganguli. (2000) EPIDEMIOLOGY OF DEMENTIA. Neurologic Clinics 18:4, 923-949
CrossRef545
Dennis J. Selkoe. (2000) THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE. Neurologic Clinics 18:4, 903-921
CrossRef546
M.Diana Neely, Lisa Zimmerman, Matthew J Picklo, Joyce J Ou, Catha R Morales, Kathleen S Montine, Venkataraman Amaranth, Thomas J Montine. (2000) Congeners of Nα-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radical Biology and Medicine 29:10, 1028-1036
CrossRef547
Julia A. Chung, Jeffrey L. Cummings. (2000) NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE. Neurologic Clinics 18:4, 829-846
CrossRef548
Amalia M. Issa, Edward W. Keyserlingk. (2000) Current and future clinical trials for alzheimer s disease: Evolving ethical concerns. Progress in Neuro-Psychopharmacology and Biological Psychiatry 24:8, 1229-1249
CrossRef549
Stephen G. Post. (2000) KEY ISSUES IN THE ETHICS OF DEMENTIA CARE. Neurologic Clinics 18:4, 1011-1022
CrossRef550
M Isaac, R Quinn, N Tabet, Mokhtar Gad El Kareem Nasr Isaac. 2000. Vitamin E for Alzheimer's disease and mild cognitive impairment. .
CrossRef551
AJ Larner. (2000) Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Expert Opinion on Therapeutic Patents 10:10, 1493-1518
CrossRef552
Xiao Qiu Xiao, Rui Wang, Xi Can Tang. (2000) Huperzine A and tacrine attenuate ?-amyloid peptide-induced oxidative injury. Journal of Neuroscience Research 61:5, 564-569
CrossRef553
Elizabeth Parks, Maret G. Traber. (2000) Mechanisms of Vitamin E Regulation: Research Over the Past Decade and Focus on the Future. Antioxidants & Redox Signaling 2:3, 405-412
CrossRef554
James M Peacock, Aaron R Folsom, David S Knopman, Thomas H Mosley, David C Goff, Moyses Szklo. (2000) Dietary antioxidant intake and cognitive performance in middle-aged adults. Public Health Nutrition 3:03,
CrossRef555
R Mason. (2000) Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Biochemical Pharmacology 60:5, 709-716
CrossRef556
Teresa Bermejo Vicedo, Francisco Jose Hidalgo Correas. 2000. Antioxidants as Therapies of Diseases of Old Age. , 343-357.
CrossRef557
Alvaro Mordente, Giuseppe Ettore Martorana, Bruno Giardina, Elisabetta Meucci, Giorgio Minotti. 2000. Biochemical and Pharmacological Properties of Coenzyme Q Analogs. , 151-160.
CrossRef558
Larry Baum, Heiko Wiebusch, Chi Pui Pang. (2000) Roles for lipoprotein lipase in Alzheimer's disease: An association study. Microscopy Research and Technique 50:4, 291-296
CrossRef559
Deborah B. Marin, Micheline Dugue, James Schmeidler, Jennifer Santoro, Judith Neugroschl, Gabrielle Zaklad, Adam Brickman, Elke Schnur, Jennifer Hoblyn, Kenneth L. Davis. (2000) The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease. International Journal of Geriatric Psychiatry 15:8, 680-686
CrossRef560
Jörg B. Schulz, Jörg Lindenau, Jan Seyfried, Johannes Dichgans. (2000) Glutathione, oxidative stress and neurodegeneration. European Journal of Biochemistry 267:16, 4904-4911
CrossRef561
M.Flint Beal. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends in Neurosciences 23:7, 298-304
CrossRef562
Denham Harman. (2000) Alzheimer’s disease: A hypothesis on pathogenesis. AGE 23:3, 147-161
CrossRef563
Ippolita Cantuti-Castelvetri, Barbara Shukitt-Hale, James A Joseph. (2000) Neurobehavioral aspects of antioxidants in aging. International Journal of Developmental Neuroscience 18:4-5, 367-381
CrossRef564
Gerard J. Byrne. (2000) Drug treatment in dementia. Current Opinion in Psychiatry 13:4, 415-421
CrossRef565
Marta Weinstock, Tamar Goren, Moussa B. H. Youdim. (2000) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Development Research 50:3-4, 216-222
CrossRef566
Ronald G. Thomas, Julie D. Berg, Mary Sano, Leon Thal. (2000) Analysis of longitudinal data in an Alzheimer's disease clinical trial. Statistics in Medicine 19:11-12, 1433-1440
CrossRef567
C Lauderback. (2000) The pyrrolopyrimidine U101033E is a potent free radical scavenger and prevents Fe(II)-induced lipid peroxidation in synaptosomal membranes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1501:2-3, 149-161
CrossRef568
Richard C. Mohs, James Schmeidler, Mosen Aryan. (2000) Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Statistics in Medicine 19:11-12, 1401-1409
CrossRef569
Manfred Gerlach, Kay L. Double, Moussa B. H. Youdim, Peter Riederer. (2000) Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotoxicity Research 2:2-3, 99-114
CrossRef570
T Suuronen. (2000) Protective effect of ?-Deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. Biochemical Pharmacology 59:12, 1589-1595
CrossRef571
F. Nourhashémi, P.J. Ousset, S. Guyonnet, S. Andrieu, Y. Rolland, D. Adoue, B. Vellas, J.L. Albarède. (2000) Maladie d'Alzheimer: De la pathogénie vers des mesures préventives ?. La Revue de Médecine Interne 21:6, 524-532
CrossRef572
Sridhar Varadarajan, Servet Yatin, Marina Aksenova, D.Allan Butterfield. (2000) Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity. Journal of Structural Biology 130:2-3, 184-208
CrossRef573
Avi L. Friedlich, M. Flint Beal. (2000) Prospects for redox-based therapy in neurodegenerative diseases. Neurotoxicity Research 2:2-3, 229-237
CrossRef574
Agneta Nordberg. (2000) Neuroprotection in alzheimer’s disease — new strategies for treatment. Neurotoxicity Research 2:2-3, 157-165
CrossRef575
H. Thomas R. Rupniak, Ken A. Joy, Charlotte Atkin, Gill Brown, Julie C. Barnes, Susan R. Doctrow, Bernard Malfroy, Tony Wong, Ian K. Anderson, Chris R. Molloy, Gary I. Mills, Peter Soden. (2000) Oxidative neuropathology and putative chemical entities for alzheimer’s disease: Neuroprotective effects of salen-manganese catalytic anti-oxidants. Neurotoxicity Research 2:2-3, 167-178
CrossRef576
Paula C Bickford, Thomas Gould, Lori Briederick, Kathy Chadman, Amber Pollock, David Young, Barbara Shukitt-Hale, James Joseph. (2000) Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. Brain Research 866:1-2, 211-217
CrossRef577
M. Said Ahmed, Wu-Yen Hung, James S. Zu, Philip Hockberger, Teepu Siddique. (2000) Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. Journal of the Neurological Sciences 176:2, 88-94
CrossRef578
P?M Bramley, I Elmadfa, A Kafatos, F?J Kelly, Y Manios, H?E Roxborough, W Schuch, P?J?A Sheehy, K-H Wagner. (2000) Vitamin E. Journal of the Science of Food and Agriculture 80:7, 913-938
CrossRef579
Kenneth Hensley, Kent A Robinson, S.Prasad Gabbita, Scott Salsman, Robert A Floyd. (2000) Reactive oxygen species, cell signaling, and cell injury. Free Radical Biology and Medicine 28:10, 1456-1462
CrossRef580
Maria Fiatarone Singh, Jeanne Wei. 2000. Cardiovascular Disease and Hypertension. , 279-316.
CrossRef581
Joshua W. Miller. (2000) Vitamin E and Memory: Is It Vascular Protection?. Nutrition Reviews 58:4, 109-111
CrossRef582
Daniel Goti, Astrid Hammer, Hans-Joachim Galla, Ernst Malle, Wolfgang Sattler. (2000) Uptake of Lipoprotein-Associated α-Tocopherol by Primary Porcine Brain Capillary Endothelial Cells. Journal of Neurochemistry 74:4, 1374-1383
CrossRef583
Jason H. T Karlawish. (2000) Why We Are Not Ready for a Biopsychosocial Approach to Dementia Research and Intervention: Commentary on ???Heterogeneity in Dementia: Challenges and Opportunities???. Alzheimer Disease and Associated Disorders 14:2, 64-67
CrossRef584
A. Martin, R. Prior, B. Shukitt-Hale, G. Cao, J. A. Joseph. (2000) Effect of Fruits, Vegetables, or Vitamin E-Rich Diet on Vitamins E and C Distribution in Peripheral and Brain Tissues: Implications for Brain Function. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 55:3, B144-B151
CrossRef585
Tom Thomas. (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease. Neurobiology of Aging 21:2, 343-348
CrossRef586
Michael J Fryer. (2000) Vitamin E as a protective antioxidant in progressive renal failure. Nephrology 5:1-2, 1-7
CrossRef587
Cornelius Ani, Sally Grantham-McGregor, David Muller. (2000) Nutritional supplementation in Down syndrome: theoretical considerations and current status. Developmental Medicine & Child Neurology 42:3, 207-213
CrossRef588
Mark P Mattson. (2000) Prostate apoptosis response-4 (Par-4): an emerging target for Alzheimer’s and Parkinson’s diseases and stroke. Expert Opinion on Therapeutic Targets 4:1, 51-63
CrossRef589
Marcos Martı́nez, Ana Isabel Hernández, Natividad Martı́nez. (2000) N-Acetylcysteine delays age-associated memory impairment in mice: role in synaptic mitochondria. Brain Research 855:1, 100-106
CrossRef590
Beth M. McLendon, Gerome G. Chen, P. Murali Doraiswamy. (2000) Current and future treatments for cognitive deficits in dementia. Current Psychiatry Reports 2:1, 20-23
CrossRef591
Sven Schippling, Anatol Kontush, Sönke Arlt, Carsten Buhmann, Hans-Jörg Stürenburg, Ulrike Mann, Tomas Müller-Thomsen, Ulrike Beisiegel. (2000) Increased lipoprotein oxidation in alzheimer’s disease. Free Radical Biology and Medicine 28:3, 351-360
CrossRef592
Claudine Berr. (2000) Cognitive impairment and oxidative stress in the elderly: Results of epidemiological studies. BioFactors 13:1-4, 205-209
CrossRef593
PEKKA RAUHALA, CHUANG C. CHIUEH. (2000) Effects of Atypical Antioxidative Agents, S-nitrosoglutathione and Manganese, on Brain Lipid Peroxidation Induced by Iron Leaking from Tissue Disruption. Annals of the New York Academy of Sciences 899:1, 238-254
CrossRef594
Corinne Jolivalt, Brigitte Leininger-Muller, Philippe Bertrand, Régine Herber, Yves Christen, Gérard Siest. (2000) Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radical Biology and Medicine 28:1, 129-140
CrossRef595
Michael W. Jann. (2000) Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease. Pharmacotherapy 20:1, 1-12
CrossRef596
Gerald Shklar, Se-Kyung Oh. (2000) Experimental Basis for Cancer Preventation by Vitamin E. Cancer Investigation 18:3, 214-222
CrossRef597
Kedar N. Prasad, Alicia R. Hovland, William C. Cole, K. Che Prasad, Piruz Nahreini, Judith Edwards-Prasad, Cynthia P. Andreatta. (2000) Multiple Antioxidants in the Prevention and Treatment of Alzheimer Disease: Analysis of Biologic Rationale. Clinical Neuropharmacology 23:1, 2-13
CrossRef598
Armand S. Schachter, Kenneth L. Davis. (2000) Alzheimer’s disease. Current Treatment Options in Neurology 2:1, 51-60
CrossRef599
P. Foley, M. Gerlach, M.B.H. Youdim, P. Riederer. (2000) MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism & Related Disorders 6:1, 25-47
CrossRef600
Joseph Knoll, Fumio Yoneda, Berta Knoll, Hironori Ohde, Ildikó Miklya. (1999) (−)1-(Benzofuran-2-yl)-2-propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. British Journal of Pharmacology 128:8, 1723-1732
CrossRef601
Casey N. Bassett, M. Diana Neely, Kathrin R. Sidell, William R. Markesbery, Larry L. Switt, Thomas J. Montine. (1999) Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer’s disease and are neurotoxic when oxidized ex vivo. Lipids 34:12, 1273-1280
CrossRef602
Kedar N. Prasad, William C. Cole, Alicia R. Hovland, K. Che Prasad, Piruz Nahreini, Bipin Kumar, Judith Edwards-Prasad, Cynthia P. Andreatta. (1999) Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Current Opinion in Neurology 12:6, 761-770
CrossRef603
Wood, Alastair J.J., , Mayeux, Richard, Sano, Mary, . (1999) Treatment of Alzheimer's Disease. New England Journal of Medicine 341:22, 1670-1679
Full Text604
Christian Behl, Florian Holsboer. (1999) The female sex hormone oestrogen as a neuroprotectant. Trends in Pharmacological Sciences 20:11, 441-444
CrossRef605
JR Evans, K Henshaw, Jennifer Evans. 1999. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. .
CrossRef606
Antonio Martin, Dena Janigian, Barbara Shukitt-Hale, Ronald L Prior, James A Joseph. (1999) Effect of vitamin E intake on levels of vitamins E and C in the central nervous system and peripheral tissues: implications for health recommendations. Brain Research 845:1, 50-59
CrossRef607
D.Allan Butterfield, Beverly Howard, Servet Yatin, Tanuja Koppal, Jennifer Drake, Kenneth Hensley, Michael Aksenov, Marina Aksenova, Ram Subramaniam, Sridhar Varadarajan, Marni E. Harris-White, Norman W. Pedigo, John M. Carney. (1999) Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sciences 65:18-19, 1883-1892
CrossRef608
Machelle M Seibel. (1999) The role of nutrition and nutritional supplements in women’s health. Fertility and Sterility 72:4, 579-591
CrossRef609
Thierry Chepda, Christian Alexandre, M. Cadau, Jacques Frey, Annette Chamson. (1999) Alpha-tocopherol as a protective agent in cell culture. In Vitro Cellular & Developmental Biology - Animal 35:9, 491-492
CrossRef610
Ching K Chow, Wissam Ibrahim, Zhihua Wei, Alvin C Chan. (1999) Vitamin E regulates mitochondrial hydrogen peroxide generation. Free Radical Biology and Medicine 27:5-6, 580-587
CrossRef611
Sanjeev Bakshi, Douglas K. Miller. (1999) ASSESSMENT OF THE AGING MAN. Medical Clinics of North America 83:5, 1131-1149
CrossRef612
D.P. Holschneider, O.U. Scremin, K. Chen, J.C. Shih. (1999) Lack of protection of monoamine oxidase B-deficient mice from age-related spatial learning deficits in the Morris water maze. Life Sciences 65:17, 1757-1763
CrossRef613
Pierre N. Tariot, Bonnie Goldstein, Carol Ann Podgorski, Christopher Cox, Nancy Frambes. (1999) Short-Term Administration of Selegiline for Mild-to-Moderate Dementia of the Alzheimerʼs Type. American Journal of Geriatric Psychiatry 6:2, 145-154
CrossRef614
John C. Adair, David J. G. Williamson, Janice E. Knoefel. (1999) Cognitive impairment in elderly who are not yet demented. Comprehensive Therapy 25:8-10, 390-396
CrossRef615
John C. S. Breitner. (1999) The end of Alzheimer's disease?. International Journal of Geriatric Psychiatry 14:7, 577-586
CrossRef616
R.W Gracy, J.M Talent, Y Kong, C.C Conrad. (1999) Reactive oxygen species: the unavoidable environmental insult?. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 428:1-2, 17-22
CrossRef617
Robert M. Russell, Helen Rasmussen, Fada. (1999) The Impact of Nutritional Needs of Older Adults on Recommended Food Intakes. Nutrition in Clinical Care 2:3, 164-176
CrossRef618
Akhlaq A Farooqui, Monica L Litsky, Tahira Farooqui, Lloyd A Horrocks. (1999) Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Research Bulletin 49:3, 139-153
CrossRef619
Qing Guo, Weiming Fu, Frederick W. Holtsberg, Sheldon M. Steiner, Mark P. Mattson. (1999) Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations. Journal of Neuroscience Research 56:5, 457-470
CrossRef620
Michael Woodward. (1999) Drug Treatments for Alzheimer's Disease. Australasian Journal on Ageing 18:2, 59-65
CrossRef621
Kenneth Hensley, Robert A. Floyd, Nai-Ying Zheng, Raha Nael, Kent A. Robinson, Xuan Nguyen, Quentin N. Pye, Charles A. Stewart, James Geddes, William R. Markesbery, Ela Patel, Gail V. W. Johnson, Guoying Bing. (1999) p38 Kinase Is Activated in the Alzheimer's Disease Brain. Journal of Neurochemistry 72:5, 2053-2058
CrossRef622
Anders Wimo, Bengt Winblad, Margareta Grafstrom. (1999) The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. International Journal of Geriatric Psychiatry 14:5, 338-347
CrossRef623
Outi Kontkanen, Eero Castrén. (1999) Trophic effects of selegiline on cultured dopaminergic neurons. Brain Research 829:1-2, 190-192
CrossRef624
Larry Baum, Lan Chen, Eliezer Masliah, Yuen Shan Chan, Ho-Keung Ng, Chi Pui Pang. (1999) Lipoprotein lipase mutations and Alzheimer's disease. American Journal of Medical Genetics 88:2, 136-139
CrossRef625
Henry Brodaty. (1999) Realistic expectations for the management of Alzheimer's disease. European Neuropsychopharmacology 9, S43-S52
CrossRef626
Eric M. Reiman, Richard J. Caselli. (1999) Alzheimer’s disease. Maturitas 31:3, 185-200
CrossRef627
Maria Angela Sortino, Angelo Battaglia, Franco Pamparana, Nicola Carfagna, Claes Post, Pier Luigi Canonico. (1999) Neuroprotective effects of nicergoline in immortalized neurons. European Journal of Pharmacology 368:2-3, 285-290
CrossRef628
J. C. Shih, K. Chen, M. J. Ridd. (1999) MONOAMINE OXIDASE: From Genes to Behavior. Annual Review of Neuroscience 22:1, 197-217
CrossRef629
Qing Guo, Lois Sebastian, Bryce L. Sopher, Miles W. Miller, Carol B. Ware, George M. Martin, Mark P. Mattson. (1999) Increased Vulnerability of Hippocampal Neurons from Presenilin-1 Mutant Knock-In Mice to Amyloid β-Peptide Tox. Journal of Neurochemistry 72:3, 1019-1029
CrossRef630
Servet M Yatin, Mustafa Yatin, Timothy Aulick, Kenneth B Ain, D.Allan Butterfield. (1999) Alzheimer's amyloid β-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neuroscience Letters 263:1, 17-20
CrossRef631
Christian Behl. (1999) Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Progress in Neurobiology 57:3, 301-323
CrossRef632
LAURA M. McCONNELL. (1999) Understanding Genetic Testing for Alzheimer Disease: Medical and Epidemiological Background. Genetic Testing 3:1, 21-27
CrossRef633
Mandy Johnstone, Andrew J.H Gearing, Karen M Miller. (1999) A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. Journal of Neuroimmunology 93:1-2, 182-193
CrossRef634
David S Cassarino, James P Bennett. (1999) An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Research Reviews 29:1, 1-25
CrossRef635
Angela Sunder, Ingrid Halle, G. Flachowsky. (1999) Vitamin e hypervitaminosis in laying hens. Archiv für Tierernaehrung 52:2, 185-194
CrossRef636
Mark A. Smith, Keisuke Hirai, Akihiko Nunomura, George Perry. (1999) Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease. Drug Development Research 46:1, 26-33
CrossRef637
Paul E. Hart, Anthony H.V. Schapira. (1999) Mitochondria: Aspects for neuroprotection. Drug Development Research 46:1, 57-66
CrossRef638
William R. Markesbery, John M. Carney. (1999) Oxidative Alterations in Alzheimer's Disease. Brain Pathology 9:1, 133-146
CrossRef639
Mark R Emmerling, Katharyn Spiegel, Edward D Hall, Harry LeVine, Lary C Walker, Roy D Schwarz, Stephen Gracon. (1999) Emerging strategies for the treatment of Alzheimer’s disease at the Millennium. Expert Opinion on Emerging Drugs 4:1, 35-86
CrossRef640
Terrie Wetle. (1998) Challenges and Directions for Gerontological Research Beyond 2000. Australasian Journal on Ageing 17, 107-110
CrossRef641
J. Hecker. (1998) Alzheimer's disease: the advent of effective therapy. Australian and New Zealand Journal of Medicine 28:6, 765-771
CrossRef642
Alan J. Sinclair, Antony J. Bayer, Jo Johnston, Catriona Warner, Simon R. J. Maxwell. (1998) Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. International Journal of Geriatric Psychiatry 13:12, 840-845
CrossRef643
Bruce N Ames. (1998) Micronutrients prevent cancer and delay aging. Toxicology Letters 102-103, 5-18
CrossRef644
Inna I. Kruman, Avindra Nath, Mark P. Mattson. (1998) HIV-1 Protein Tat Induces Apoptosis of Hippocampal Neurons by a Mechanism Involving Caspase Activation, Calcium Overload, and Oxidative Stress. Experimental Neurology 154:2, 276-288
CrossRef645
B BAIR. (1998) FREQUENTLY MISSED DIAGNOSIS IN GERIATRIC PSYCHIATRY. Psychiatric Clinics of North America 21:4, 941-971
CrossRef646
1998. Vitamin E Tocopherols And Tocotrienols. .
CrossRef647
KENICHI KITANI, SETSUKO KANAI, GWEN O. IVY, MARIA CRISTINA CARRILLO. (1998) Assessing the Effects of Deprenyl on Longevity and Antioxidant Defenses in Different Animal Models. Annals of the New York Academy of Sciences 854:1 TOWARDS PROLO, 291-306
CrossRef648
M. MEYDANI, R. D. LIPMAN, S. N. HAN, D. WU, A. BEHARKA, K. R. MARTIN, R. BRONSON, G. CAO, D. SMITH, S. N. MEYDANI. (1998) The Effect of Long-term Dietary Supplementation with Antioxidantsa. Annals of the New York Academy of Sciences 854:1 TOWARDS PROLO, 352-360
CrossRef649
St
CrossRef650
CHAIR: RUSSEL J. REITER. (1998) Roundtable Discussion: How Best to Ensure Daily Intake of Antioxidants (from the Diet and Supplements) That is Optimal for Life Span, Disease, and General Health. Annals of the New York Academy of Sciences 854:1 TOWARDS PROLO, 463-476
CrossRef651
David Holzman. (1998) Ginkgo biloba for Alzheimer's Disease. Alternative and Complementary Therapies 4:5, 361-363
CrossRef652
Serge Gauthier. (1998) Clinical trials and therapy. Current Opinion in Neurology 11:5, 435-438
CrossRef653
Barry Baumel. (1998) Easing the burden of Alzheimer's disease: therapeutic options. European Journal of Neurology 5:S4, S19-S29
CrossRef654
N. Delanty, M. A. Dichter. (1998) Oxidative injury in the nervous system. Acta Neurologica Scandinavica 98:3, 145-153
CrossRef655
Suhr, Ando, Ohlsson, Olofsson, Andersson, Lundgren, Ando, Holmgren. (1998) Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. European Journal of Clinical Investigation 28:8, 687-692
CrossRef656
Charlene Compher, Joan G. Bader. (1998) Nutritional Requirements of an Aging Population with Emphasis on Subacute Care Patients. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9:3, 441-450
CrossRef657
Martin Knapp, David Wilkinson, Rachel Wigglesworth. (1998) The economic consequences of Alzheimer's disease in the context of new drug developments. International Journal of Geriatric Psychiatry 13:8, 531-543
CrossRef658
S. E. Gariballa, A. J. Sinclair. (1998) Nutrition, ageing and ill health. British Journal of Nutrition 80:01, 7
CrossRef659
Kimberly B. Bjugstad, William D. Flitter, William A. Garland, George C. Su, Gary W. Arendash. (1998) Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Research 795:1-2, 349-357
CrossRef660
JORGE BUSCIGLIO, JULIE K. ANDERSEN, HYMAN M. SCHIPPER, GAD M. GILAD, RICHARD McCARTY, FULVIO MARZATICO, OLIVIER TOUSSAINT. (1998) Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanismsa. Annals of the New York Academy of Sciences 851:1 STRESS OF LIF, 429-443
CrossRef661
N.C. Berchtold, C.W. Cotman. (1998) Evolution in the Conceptualization of Dementia and Alzheimer’s Disease: Greco-Roman Period to the 1960s. Neurobiology of Aging 19:3, 173-189
CrossRef662
Frank Lezoualc'h, Mauro Sparapani, Christian Behl. (1998) N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-?B. Journal of Pineal Research 24:3, 168-178
CrossRef663
Tanuja Koppal, Ram Subramaniam, Jennifer Drake, M.Renuka Prasad, Harbhajan Dhillon, D.Allan Butterfield. (1998) Vitamin E protects against Alzheimer's amyloid peptide (25–35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Research 786:1-2, 270-273
CrossRef664
William J. Burke, Bruce S. Kristal, Byung P. Yu, Shu Wen Li, Tien-Sung Lin. (1998) Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Research 787:2, 328-332
CrossRef665
Winnie Chan, Richard J. Krieg, Edward P. Norkus, James C.M. Chan. (1998) α-Tocopherol Reduces Proteinuria, Oxidative Stress, and Expression of Transforming Growth Factor β1 in IgA Nephropathy in the Rat. Molecular Genetics and Metabolism 63:3, 224-229
CrossRef666
Joseph Knull. (1998) (-)Deprenyl (Selegiline), a Catecholaminergic Activity Enhancer (CAE) Substance Acting in the Brain. Pharmacology & Toxicology 82:2, 57-66
CrossRef667
Frank L. Heppner, Karl Roth, Robert Nitsch, Nils P. Hailer. (1998) Vitamin E induces ramification and downregulation of adhesion molecules in cultured microglial cells. Glia 22:2, 180-188
CrossRef668
H Allain, D Bentué-Ferrer, O Zekri, S Schück, S Lebreton, JM Reymann. (1998) Experimental and clinical methods in the development of anti-Alzheimer drugs. Fundamental & Clinical Pharmacology 12:1, 13-29
CrossRef669
Jaak Panksepp. (1998) The Quest for Long-Term Health and Happiness: To Play or Not to Play, That Is the Question. Psychological Inquiry 9:1, 56-66
CrossRef670
Yutaka Sagara, Shirlee Tan, Pamela Maher, David Schubert. (1998) Mechanisms of resistance to oxidative stress in Alzheimer's disease. BioFactors 8:1-2, 45-50
CrossRef671
David B. Teplow. (1998) Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 5:2, 121-142
CrossRef672
Christopher J Fowler. (1997) The role of the phosphoinositide signalling system in the pathogenesis of sporadic Alzheimer's disease: a hypothesis. Brain Research Reviews 25:3, 373-380
CrossRef673
Jaswinder S Bains, Christopher A Shaw. (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Research Reviews 25:3, 335-358
CrossRef674
Mark P. Mattson. (1997) Advances fuel Alzheimer's conundrum. Nature Genetics 17:3, 254-256
CrossRef675
Alan A. Boulton, Bruce A. Davis, David A. Durden, Lillian E. Dyck, Augusto V. Juorio, Xin-Min Li, I. Alick Paterson, Peter H. Yu. (1997) Aliphatic propargylamines: New antiapoptotic drugs. Drug Development Research 42:3-4, 150-156
CrossRef676
Joseph Grimsby, Miklos Toth, Kevin Chen, Takeshi Kumazawa, Lori Klaidman, James D. Adams, Farouk Karoum, Judit Gal, Jean C. Shih. (1997) Increased stress response and β–phenylethylamine in MAOB–deficient mice. Nature Genetics 17:2, 206-210
CrossRef677
(1997) Alpha-Tocopherol and Alzheimer's Disease. New England Journal of Medicine 337:8, 572-573
Full Text678
Bernd Moosmann, Manfred Uhr, Christian Behl. (1997) Neuroprotective potential of aromatic alcohols against oxidative cell death. FEBS Letters 413:3, 467-472
CrossRef679
Michael Williams, Robert E Davis. (1997) Alzheimer’s disease and related dementias: prospects for treatment. Expert Opinion on Investigational Drugs 6:6, 735-757
CrossRef680
Drachman, David A., , Leber, Paul, . (1997) Treatment of Alzheimer's Disease — Searching for a Breakthrough, Settling for Less. New England Journal of Medicine 336:17, 1245-1247
Full Text681
Thomas Wisniewski, Jorge Ghiso, Blas Frangione. (1997) Biology of Aβ Amyloid in Alzheimer's Disease. Neurobiology of Disease 4:5, 313-328
CrossRef682
Frank J. Kelly. (1997) Vitamin E: its time has nearly come. Nutrition & Food Science 97:6, 239-241
CrossRef
- Letters
